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Mechanisms of immune tolerance and suppression occur early at the site of developing 
tumors and inhibit protective responses induced by cancer vaccines, limiting their 
efficacy in the treatment of cancer. Combinatorial approaches to cancer immunotherapy 
were used to investigate the simultaneous inhibition of suppressive signals in the tumor 
microenvironment and induction of protective T cell responses. The inhibition of an 
immune checkpoint, LAG-3, in a mouse model of HER-2/neu-overexpressing mammary 
adenocarcinoma was found to improve CD8
+
 T cell function in an intrinsic manner when 
used in combination with a GM-CSF-secreting whole cell vaccine and Treg depletion. 
LAG-3 signaling also altered the phenotype of antigen-presenting cells in the tumor-
draining nodes of mice.  Early mechanisms of immune tolerance in a mouse model of 
pancreatic cancer development were characterized and targeted with Treg depletion and 
an attenuated Listeria vaccine targeting mutated Kras. Local, but not systemic, T cell 
responses were found to correlate with survival and the alteration of the tumor 
microenvironment towards an anti-cancer response. In both models of cancer, 
combination immunotherapy incorporating a vaccine and immunomodulation of the 
tumor microenvironment was necessary for successful immune responses that inhibited 
the progression of cancer.  
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CHAPTER 1: INTRODUCTION 
 
The Status of the “War on Cancer” 
Cancer, the second leading cause of death in the United States, is a disease that 
will directly affect approximately one in two people at some point during their life 
1
.  
Survival rates have improved for some cancers due to early detection and more effective 
treatments; however, it is predicted that 1 in 4 people in the United States will succumb 
to cancer 
1
. In the lab of Dr. Elizabeth Jaffee, we are focused on two particularly common 
and lethal cancers. Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause 
of cancer deaths in men and women in the United States, with five year survival rates 
ranging from 1-14% depending on the stage at which it is diagnosed 
2,3
.  The standard of 
treatment for pancreatic cancer, depending on stage, includes surgery, chemotherapy and 
radiation; gemcitabine, the most commonly used chemotherapeutic agent used in both 
early and late stage PDA gives patients a survival benefit of just a few additional months 
3
. Despite improvements in the detection, prevention, and treatment of breast cancer over 
the past few decades, breast cancer remains the most commonly diagnosed cancer and the 
second most common cancer-related cause of death in women 
1
.  Five year survival rates 
for all stages of breast cancer approach 75%; however, for more advanced breast cancers 
that have metastasized to other organs, that rate falls to 24% 
1
. Even given recent 
treatment advances and scientific breakthroughs in the underlying biology of cancer, 





The promise of immunotherapy for cancer 
 Inflammation has been linked to cancer and has been shown to include both 
protective immune responses to tumor antigens and pro-oncogenic inflammatory cells 
which suppress the anti-cancer response 
4
. The effectiveness of immunotherapy may rely 
on intervention in the timeframe in which this inflammatory response can still be re-
directed to a protective, anti-cancer response 
5
. Cancer vaccines attempt to harness the 
power of the body’s protective immune response to eliminate cancer and bypass tolerance 
mechanisms. Cancer vaccines and immunotherapy have several advantages over 
conventional therapies for cancer. T and B cell responses to tumor antigens are specific, 
unlike chemotherapy and radiation, and therefore, have the potential for efficacy with few 
adverse effects. Due to the ability to generate novel immune responses through the 
recombination of the T and B cell receptor subunits, immunotherapy also has the 
advantage of adapting and evolving with tumors that acquire frequent mutations, as well 
as long-lasting memory responses, so there is potential for long-term benefits.  Two novel 
cancer therapies utilizing the immune system to fight cancer, a dendritic cell vaccine and 
an immune checkpoint inhibitor, have recently been FDA-approved, bringing 
immunotherapy into the mainstream 
6,7
. However, benefits seen with these 
immunotherapies in comparison to conventional treatments are still small (though 
significant) and many other immune-modulating agents have had little success in clinical 
trials for cancer patients.  The challenges posed by pre-existing T cell tolerance and 
tumor immune evasion in patients have been the source of much investigation as the 




The challenge of tolerance and immunosuppression 
The potential of immunotherapy combined with its failures in the treatment of 
cancer demands a deeper understanding of how to induce and direct the best immune 
response. Cancer patients have been shown to harbor tumor antigen-specific T cells and 
antibodies, even in the setting of advanced disease, demonstrating that the generation of 
an immune response is not sufficient for protection against disease 
8,9
. There are many 
mechanisms that tumors possess for downregulating the anti-tumor response, including 
recruiting and inducing myeloid derived suppressor cells (MDSC) and regulatory T cell 
populations (Treg), enhancing secretion directly and indirectly of anti-inflammatory 
cytokines such Transforming Growth Factor beta (TGF) and IL-10, and upregulating 
inhibitory ligands 
10





 T cells, as well as APCs which are responsible for activating the T cell 
response to cancer. As a result, APCs (such as dendritic cells), no longer support the anti-
tumor immune response, but rather are tolerogenic 
10
.  There are many more mechanisms 
of immunosuppression used by tumors to evade the immune system, including those that 
have been described and those yet to be uncovered.  
 
T regulatory cells 
One subset of inhibitory CD4
+
 lymphocytes, T regulatory cells (Tregs), has been 
shown to correlate with poor prognosis and metastasis in cancer patients 
11-15
. Depleting 
Tregs has been shown to be beneficial to survival and now is a therapeutic goal of many 
immune-based approaches to cancer treatment 
16,17
. There are many mechanisms that are 
4 
 
utilized by Tregs to dampen the anti-cancer immune response that explain the benefit of 
depleting Tregs in cancer patients.  
Different Treg subsets have been shown to be capable of  producing 





 T lymphocytes, skew differentiation of CD4
+
 T cells away 
from a Th1/Th2 effector subset and towards Treg, and tolerize APCs 
18-20
. TGF also 
controls B cell class switching from IgG to IgA, suppresses the proliferation of B cells, 
induces suppressive N2 type neutrophils, and results in the production of angiogenic 
factors such as VEGF and extracellular matrix remodeling factors such as matrix 
metalloproteases that aid in tumor metastasis 
21-25
. Immature dendritic cells induced by 
IL-10 and TGF result in less antigen presentation and downregulation of CD40, CD80, 
and CD86 co-stimulatory molecule expression 
26,27
. Furthermore, direct suppression of 
effector T cells by Tregs has also been suggested, through both competition for IL-2 in 





“Immune checkpoint” signals that turn off T cell function exist as a natural 
mechanism to dampen signaling that occurs downstream of the TCR when cognate 
antigen is encountered, in order to prevent excessive activation of the immune system and 
resulting tissue damage. The most notable example of an immune checkpoint is CTLA-4, 
a molecule on the surface of T lymphocytes, which binds to CD80 and CD86 (B7.1 and 
B7.2) as does the costimulatory ligand CD28, but with the opposite effect on TCR 
5 
 
signaling. Immune checkpoint molecules have been found to be expressed by tumor-
infiltrating lymphocytes (TIL) with impaired ability to secrete multiple cytokines in 
response to tumor antigen and therefore, serve as markers of T cell “exhaustion.”  When 
CTLA-4 signaling is blocked by a monoclonal antibody (now approved for the treatment 
of metastatic melanoma), its inhibition of effector T cells is released, allowing for 
powerful anti-tumor effects 
28
. The anti-tumor effects of CTLA-4 blockade are 
accompanied, however, with severe autoimmune adverse effects, which may be related to 
its expression on Tregs as well as effector cells 
28,29
. Additional immune checkpoint 
molecules found to be upregulated on dysfunctional T cells include LAG-3, PD-1, Tim-3 
and Adenosine 2a Receptor (A2aR) 
30-32
. Blockade of PD-1 and its ligand, B7-H1 (PD-
L1), have also been found to be effective in mouse models and clinical trials, with some, 
but not as severe, autoimmunity as CTLA-4 blockade 
6,33
.  
Similarly to CTLA-4 and PD-1, blockade of LAG-3 signaling with antibody 
treatment or knockout of LAG-3 in effector CD8
+
 T cells can result in increased 
activation and tumor infiltration by T cells 
30
. However, LAG-3 seems responsible for 
fine-tuning of the T cell response rather than a master on/off switch, as there is no 
autoimmunity observed in LAG-3 knockout mice, except in combination with PD-1 
deletion 
34
.  Additionally, in patient TIL, suppression of LAG-3 signaling alone was not 
sufficient for complete reversal of dysfunction 
35
. However, LAG-3 has also been found 
to be expressed by other cell types, such as Tregs and plasmacytoid dendritic cells (DC), 
and there may be a role for LAG-3 in signaling to the APC through MHC II 
36,37
. As 
cancer patients harbor tolerized APCs and Tregs within the tumor microenvironment, 
determining the effect of LAG-3 in these populations, as well as in CD8
+ 
T cells, is an 
6 
 
important goal and makes LAG-3 an attractive candidate for blockade in the treatment of 
cancer. 
 
Innate suppressive cells  
The paradigm of pro- or anti-tumorigenic populations as with suppressive CD4
+
 T 




 T cells also pertains to 
innate cells of the immune system. Tumor-associated macrophages have been identified 
as an important pro-oncogenic cell type in the tumor microenvironment, enhancing 
metastasis through interaction with CD4
+
 T cells, promoting angiogenesis, and inhibiting 
anti-tumor immune responses 
13,38,39
. However, compared with tumor-associated “M2” 
macrophages, mature macrophages of the “M1” phenotype are known to promote the 
anti-tumor immune response and are associated with a favorable prognosis 
40,41
. 
Similarly, the duality of anti- or pro-tumor phenotype exists for neutrophils. Tumor-
associated “N2” neutrophils have been shown to promote metastasis and angiogenesis by 
secreting matrix mellatoproteinase-9 and neutrophil elastase and to suppress T cell 
responses by production of arginase 
42
. N2 neutrophils have been found in untreated 
mouse tumors, contributing to tumor progression; however, they can be converted to 




In addition to tolerized DCs, N2 neutrophils, and M2 macrophages in the tumor 
microenvironment, MDSC, a mixed population of immature monocytic and granulocytic 
cells, can contribute to the pro-oncogenic inflammatory milieu in the microenvironment 
7 
 
and suppress effector T cells. MDSC express high levels of arginase which results in a 
depletion of the arginine in their extracellular environment that is required for production 
of new CD3 zeta chain molecules, leading to TCR downregulation 
43,44
. MDSC can also 
sequester other essential metabolites such as cysteine and tryptophan required for T cell 
proliferation and cytokine secretion 
44,45
. Another mechanism that leads to tumor antigen-
specific tolerance by MDSC is via the nitrosylation of tyrosine residues in the TCR by 
production of reactive oxygen species and peroxynitrates, preventing downstream 




Tolerance in the neu-N and KPC mouse models 
As discussed generally throughout this section, many immune tolerance 
mechanisms are in place by tumors to escape the protective immune response. These 
have also been observed in the two mouse models utilized in my thesis. In the neu-N 
mouse model in which the proto-oncogene HER2/neu (neu) is over-expressed in 
mammary tissue, there is tolerance to the neu antigen as evidenced by a deficient T cell 
and antibody response to neu-targeted vaccination that fails to protect from neu-
expressing tumors 
48
. However, treatment with the neu–targeted vaccine (3T3neuGM) in 
combination with low dose cyclophosphamide (Cy) to deplete Tregs, can uncover a high 
avidity population of T cells, such as exists in vaccinated wild type parental strain mice, 
with the result that a small percentage of these mice can reject established tumors 
49
. In 
the neu-N mice, an adoptive transfer of high avidity CD8
+
 T cells specific for neu can 
result in tumor rejection when given in combination with Cy and 3T3neuGM; however, 
8 
 
these cells fail to reach full potency as seen in wild type tumor-bearing mice in terms of 
the dose of T cells needed to control tumors and the amount of cytokines produced 
50
.  




;Pdx-1-Cre mouse model, mice express mutated 
Kras and p53 proteins in the pancreas and develop pancreatic intraepithelial neoplasms 
(PanIN), precursors that progress to invasive pancreatic ductal adenocarcinoma (PDA).  
There is early evidence of immunosuppression in KPC mice, starting in the earliest stage 





. Additionally, pancreatic cancer has a unique biology in its characteristic stromal 
response, often termed “desmoplasia,” which contributes to its extreme treatment 
resistance. Oncogenic signals derived from the tumor cells can induce pancreatic stellate 
cells to secrete extraceullar matrix proteins such as collagen and hyaluronan leading to 
elevated interstitial pressure 
3,52
. Pancreatic cancer is also characterized by a relative 
hypovascularity, in comparison to most tumors which become hypervascular through 
angiogenic processes 
53
. The impenetrable stroma and hypovascularity impair the 
delivery of chemotherapy, and it has been shown that the inhibition of stromal signaling 
pathways such as the Sonic Hedgehog pathway is required for improved delivery of 
gemcitabine 
54
.  Thus, both immune and non-immune populations in the stroma 
contribute to a microenvironmental milieu that is suppressive to conventional and 
immune-based therapy.  The observations of multiple tolerance mechanisms active in the 
mouse models of pancreatic and breast cancer correlate with the profound T cell 
dysfunction and exhaustion of TIL observed in cancer patients, as well as evidence of 
Tregs and suppressive innate cell populations in human tumors. These mice provide 
9 
 
clinically relevant models of early and late stage cancer to investigate the use of cancer 
vaccines along with additional therapies to overcome immune suppression.   
 
Overview of this Thesis Work: 
The overall goal of this dissertation is to explore the effects of inhibiting 
immunosuppressive signals in the tumor microenvironment to improve upon the progress 
made thus far with immunotherapy to treat cancer. In two separate but related projects, I 
have:  
1. Studied the inhibition of an immune checkpoint molecule, LAG-3, as a signal 
that controls the potency of tumor antigen-specific CD8
+
 T cells 
2. Investigated the role of LAG-3 on other immune cell populations present in 
the tumor microenvironment and the subsequent effects on tumor immunity  
3. Evaluated a novel combination of a Listeria vaccine targeting a mutant allele 
of Kras and Treg depletion in altering the course of pancreatic cancer 
progression in a mouse model of PDA development 
4. Characterized the immunosuppressive signals present in the early stages of 
pancreatic cancer and the ability of immunotherapy to alter these signals 
 
In chapter 2, the role of LAG-3 in tumor immunity is explored in the HER2/neu 
mouse model. However, the mouse model of pancreatic cancer utilized in chapter 3 
provided a more relevant model in terms of understanding how cancer develops and 
progresses in its natural site of development with all of the interactions between tumor, 
immune, and stromal cell populations intact. Due to this reasoning as well as technical 
10 
 
difficulties in this first project, I switched my focus and energy to the second project. In 
chapter 3, the second project, characterizing the effect of immunotherapy on earlier 





CHAPTER 2: THE ABSENCE OF LYMPHOCYTE ACTIVATION GENE 3 
(LAG-3) ENHANCES ANTIGEN-SPECIFIC T CELL FUNCTION 
INTRINSICALLY IN THE HER-2/NEU BREAST CANCER MODEL 
 
Introduction 
 Transgenic mice expressing the rat proto-oncogene neu under the control of the 
MMTV mammary-specific promoter (neu-N mice) that develop spontaneous mammary 
adenocarcinoma tumors are a clinically relevant model of breast cancer that closely 
mimics the immune tolerance seen in cancer patients 
55
. neu-N mice exhibit a poor anti-
tumor immune response following vaccination with a HER-2/neu and GM-CSF-
expressing irradiated whole cell vaccine compared to wild type mice of the same genetic 
background (FVB/N) 
48
. The majority of the T cell receptors (TCR) of CD8
+
 T cells in 
vaccine-alone treated neu-N mice are of low avidity for the immunodominant epitope of 
HER-2/neu, RNEU420-429 
56
. However, with the addition of low dose cyclophosphamide 
(Cy), a Treg depleting agent, to the vaccine regimen, 20% of neu-N mice develop a high 
avidity anti-neu CD8
+ 
T cell response, similar to what is seen in FVB/N mice after 
vaccination, and are protected from tumor challenge 
49
. High avidity (from vaccinated 
FVB/N mice) and low avidity (from vaccinated neu-N mice) TCR sequences specific for 
HER-2/neu were cloned and TCR transgenic mice were created to use as a source of 
CD8
+ 
T cells for further study. In neu-N mice, both high avidity (HA) and low avidity 
(LA) adoptively transferred T cells are unable to produce the same level or number of 
effector cytokines as when the respective HA or LA CD8
+
 T cells are transferred into 
FVB/N mice 
50
. The majority of HA cells transferred into neu-N tumor bearing mice 
12 
 
produce low levels of IFN and very little to no TNF or IL-2 whereas HA cells 
transferred into FVB-N mice have the capability to secrete multiple cytokines (known as 
polyfunctionality) in response to neu-expressing tumors. Administration of Cy with 
vaccine enhances cytokine production in HA cells in comparison to vaccine alone-treated 
neu-N mice. LA cells are severely impaired in cytokine production in neu-N mice, even 
in the presence of Cy and vaccine, and fail to protect against tumor challenge 
50
. 
 Exhausted T cells in tumor-bearing mice or cancer patients show upregulation of 
immune checkpoints, such as PD-1, CTLA-4, and LAG-3, and blockade of these 
checkpoints has been found to be efficacious in both the clinical setting and in mouse 
models of cancer 
6
. LAG-3, an immune checkpoint molecule, structurally related to CD4 





 T cells 
30,36,57
. Blockade of LAG-3 with a monoclonal antibody or 
by genetic deletion results in increased T cell proliferation and IFN production by model 
tumor antigen-specific CD8
+
 T cells in combination with a vaccine; however, it has also 
been shown that blockade of more than one checkpoint is required in human TIL for 
function to be completely restored 
30,35
. I hypothesized that deletion of LAG-3 expression 
in HA and LA T cells would reverse the CD8
+
 T cell dysfunction seen in tumor-bearing 
neu-N mice and result in greater survival when mice are treated in combination with 
Treg-depleting Cy and a whole cell vaccine targeting neu and expressing GM-CSF.  I 
hypothesized that with modulation of immune checkpoints, the function of HA T cells in 
neu-N mice could be recovered to the level of that seen in non-tolerant FVB/N mice and 
that LA T cells would also recover some, if still limited, effector function. As LAG-3 can 
13 
 
be expressed by CD4
+
 T cells, B cells, NK cells, and plasmacytoid dendritic cells (DCs), 
I also predicted that deletion of LAG-3 in tumor antigen-tolerant mice would have CD8
+
 
T cell-extrinsic effects, resulting in enhanced tumor immunity and impaired tumor 
growth 
58,59





 T cells more effectively infiltrated mammary tumors, had increased 
polyfunctionality, and had enhanced ability to clear tumors in neu-N mice compared to 
HA cells. However, I was unable to repeat these results consistently in this model, 
perhaps due to technical issues with the mouse colony. Abrogation of endogenous LAG-3 





 T cells compared to their function in neu-N mice with intact LAG-3 
expression, suggesting contradictory roles for LAG-3 in T cells and non-T cells. 
Additionally, LA cells did not show the same ability in regards to enhanced tumor 











Materials and Methods 
Mice  
Female 6-12 week old mice were used for all experiments. FVB/N mice (Harlan 
Laboratories) and neu-N mice (Jackson Laboratory) were purchased and then further 
propagated at Johns Hopkins.  FVB/N Thy1.2
+
 mice were created by backcrossing the 
Thy1.2 allele onto the FVB/N background for 10 generations. TCR transgenic mice were 
generated using TCR sequences from high-avidity (HA) and low-avidity (LA) RNEU
420-
429
-specific T-cell clones, crossed to the FVB/N Thy1.2
+
, and phenotyped with V, 
Thy1.2, and tetramer staining as previously described 
50
. The high avidity TCR pairs the 





 mice were kindly provided by Charles Drake (Johns Hopkins University) and 
have germline deletion of LAG-3 as originally described 
60
. Both HA and LA TCR 
transgenic mice were crossed with LAG-3
-/-
 mice after backcrossing the LAG-3
-/- 
mouse 
from C57BL/6 genetic background onto the FVB/N genetic background. These HA and 
LA TCR transgenic LAG-3
-/-
 mice were also crossed to FVB/N mice that express the 
Thy1.2 marker for some experiments to identify adoptively transferred T cells versus 
endogenous T cells in neu-N mice (expressing Thy1.1). neu-N mice were crossed to 
LAG-3
-/-
 mice to generate neu-N LAG-3
-/-
 mice, on a FVB/N Thy1.1 genetic background. 
Once stable colonies were established, genotyping was performed at regular intervals to 
ensure integrity of the transgenes. Animals were kept in pathogen-free conditions and 
treated in accordance with institutional and American Association of Laboratory Animal 
15 
 
Committee approved policies. All animal studies were approved by the Institutional 
Animal Care and Use Committee of the Johns Hopkins University. 
 
Cell lines  
 The neu-expressing mammary adenocarcinoma cell line, NT2.5, originally 
derived from a neu-N spontaneous tumor, was maintained in RPMI with 20% fetal 
bovine serum, 1.2% HEPES, 1% L-glutamine, 1% non-essential amino acids, 1% sodium 
pyruvate, 0.5% penicillin-streptomycin, 0.2% insulin, and 0.02% gentamycin 
48
.  The 
3T3neuGM cell line, expressing neu and GM-CSF and used as a whole cell vaccine, was 
generated as previously described and grown in DMEM with 10% bovine calf serum, 1% 
sodium pyruvate, 0.5% penicillin-streptomycin, and 0.3  methotrexate selection 
48
.   
The T2-D
q
 cells were derived as previously described and grown in RPMI with 10% 
FBS, 1% L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids, 0.5% 
penicillin-streptomycin, and 0.68% hygromycin B 
56
.   
 
Cy and vaccine administration  
 Cyclophosphamide (Cytoxan, Cy, Bristol Myers Squibb) was reconstituted in 
sterile water at 20 mg/ml and then diluted in sterile PBS. Cy (100 mg/kg) was given as an 
intra-peritoneal injection (IP) of 0.5 ml one day prior to vaccine according to treatment 
group. neu and GM-CSF-expressing 3T3neuGM vaccine cells were irradiated at 50 Gy 
and injected subcutaneously (SC) at a dose of 3 x 10
6
 cells per mouse, divided into three 
16 
 
0.1ml injections in PBS in the left axillary lymph node regions and right and left inguinal 
lymph node regions.    
 
Tumor clearance studies  
Mice were given SC injections into the right upper mammary fat pad of 2 x 10
6
 
(FVB/N) and 5 x 10
4
 (neu-N and neu-N LAG-3
-/-
) NT2.5 cells in 0.1ml PBS 3 days prior 
to vaccine 
48
. Tumors were measured every 3 days and mice were euthanized when 
tumors grew to over 1 cm
2 
in accordance with Animal Care and Use Committee 
guidelines.  
 
Adoptive transfer  
CD8
+
 T cells were isolated from harvested spleens and lymph nodes of TCR 
transgenic mice using Dynabeads untouched mouse CD8
+
 cells (Invitrogen) negative 




 T cells, 10 
g V4 and V6 depleting antibodies (BD Pharmingen) were added to the negative 
selection antibody cocktail to enhance purity of the adoptively transferring T cell 
population. 6 x 10
6
 cells were injected intraveneously (IV) in 0.5 ml for flow cytometry 
analysis or in the decreasing doses indicated for tumor clearance studies one day after 
vaccination.  
 
T cell Trafficking and Cytokine Production Assays  
17 
 
 For evaluation of cytokine production and T cell trafficking, NT2.5 cells were 
given to mice at a dose of 5 x 10
6
 (FVB/N) and 1 x 10
6
 (neu-N and neu-N LAG-3
-/-
), 8 
days prior to vaccination, unless otherwise specified. T cells isolated from spleens, 
vaccine or tumor-draining nodes, and tumors were harvested 3 or 5 days after adoptive 
transfer and stimulated with peptide and T2-D
q
 cells for 5 hours in the presence of a 
protein transport inhibitor (GolgiStop, BD Biosciences) for intracellular cytokine assays 
50,61
. Tumors were digested in hyaluronidase and collagenase-containing media for 1 hour 





peptides were produced in the Johns Hopkins Biosynthesis and Sequence Facility at a 
purity >95% 
50
. Adoptively transferred cells were identified by surface staining with 
fluorescently conjugated antibodies for CD8 and either the V4 chain or Thy1.2 marker 
in FACS buffer. The following stains and antibodies were used: Live/Dead Fixable Dead 
Cell Stain Kit (Invitrogen Molecular Probes), Thy1.2-Alexa Fluor 700 (BioLegend), 
CD8-Pacific Blue, V4- Fluorescein isothiocyanate (FITC), CD49f- Phycoerythrin (PE) 
(BioLegend), CD49d-FITC (BD Pharmingen), CD29-Alexa Fluor 647 (BioLegend), 
CXCR3- Peridinin chlorophyll (PerCP)-Cyanine (Cy)5.5 (eBioscience), IFN-PerCP-
Cy5.5 (BD Pharmingen), IL-2- Allophycocyanin (APC) (BD Pharmingen), TNF-Alexa 
Fluor 700 (BD Pharmingen), Granzyme B-PE (eBioscience), CD107a and b-PE-Cy7 (BD 
Pharmingen), Tbet-PE (eBioscience), CD11c-PerCP (BioLegend), CD86-Pacific Blue 
(BioLegend), CD80-Alexa Fluor 647 (BioLegend), CD40-FITC (BD Pharmingen), IL-
12-PE (BD Pharmingen), and MHC II (I-A/I-E)-Alexa Fluor 700 (Biolegend).  For 
intracellular protein staining, cells were permeabilized with CytoFix Fixation Buffer and 
18 
 
washed with Perm/Wash Buffer (BD Biosciences). To stain for intranuclear transcription 
factors, the PE anti-mouse/rat Foxp3 staining set (eBioscience) was used to fix and 
permeabilize, and stain cells. FcBlock was routinely used prior to staining (anti-
CD16/CD32 antibody, BD Biosciences). Flow cytometry was performed using 
FACSCalibur and LSR II instruments (BD Biosciences) and analyzed using FlowJo (Tree 
Star, Inc.) and FACSDiva (BD Biosciences), depending on the number of fluorochromes 
utilized.  
 
In vitro stimulation  
 4 days post vaccination of neu-N and neu-N LAG-3
-/-
 mice, vaccine-draining 
lymph nodes (axillary, inguinal) were harvested and CD11c MicroBeads (Miltenyi Biotec 
Inc.) were used to isolate with CD11c
+
 cells. Naïve CD8
+
 T cells were isolated by 
negative isolation from the spleens of TCR transgenic mice and CFSE labeled with 1.5 









 T cells per well in a 96 well U-bottom plate for 3, 5, or 
7 days at 37°C and 5% CO2 in RPMI supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, 0.5% L-glutamine, and 50 M 2-mercaptoethanol.  Golgistop 
was incubated with cells for 5 hours prior to staining and flow cytometry analysis.  
 
Data analysis 
For analyzing polyfunctional cytokine data, Pestle and SPICE software were used, 
as provided by Mario Roederer (NIAID Vaccine Research Center) 
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peptide was normalized for response to the negative control 
NP
118-126 
peptide. Statistical significance was analyzed using GraphPad Prism (GraphPad 
Software, Inc.) and assessed using a two-tailed student T test unless otherwise noted.  












 T cells, given in combination with Cy and the 3T3neuGM vaccine have 
been shown to mediate tumor rejection (100% tumor-free with 6 x 10
6
 cells, 75% with 4 
x 10
6
 cells) in neu-N mice 
50
. A dose titration experiment of decreasing numbers of cells 
starting with 6 x 10
6
 HA and HA LAG-3
-/-
 cells was used to compare differences in the 
ability to control neu-expressing NT2.5 tumors in neu-N mice. It was demonstrated that 
HA LAG-3
-/-
 T cells are superior to HA T cells in their ability to clear tumors in neu-N 
mice at lower doses of cells, an effect that was dependent on Cy treatment (Figure 1). 
Mice receiving HA LAG-3
-/-
 cells cleared tumor regardless of dose, with the exception of 
1 out of 2 mice in the 4 x 10
6
 dose, whereas wild type HA cells required a dose of 6 x 10
6
 
cells or higher to remain tumor-free as 1 out of 2 mice developed tumors in this dose and 
2 out of 2 mice developed tumors in the medium and low dose of HA cells. With the 
vaccine alone, there was no difference between the HA LAG-3
-/-
 and HA CD8
+
 T cells at 









 T cells were adoptively transferred into neu-N mice 10 days after tumor 
implantation, one day following vaccination and 2 days after Cy. T cells were isolated 
from the harvested tumor-draining lymph nodes and tumors of neu-N mice 5 days post-
21 
 
transfer and identified by staining for the Thy1.2 marker. As previously published, Cy 
enhanced the ability of T cells to traffic into tumors and both HA and HA LAG-3
-/-
 cells 
were found in significantly increased numbers in the presence of Cy compared to vaccine 
alone in tumors (Figure 2A). Cy enhanced the trafficking of HA T cells into the tumor-
draining nodes as well (Figure 2B). Although it was not significant, there was a trend 
towards increased cell number per mg of tumor or per lymph node in the HA LAG-3
-/-
 
groups compared to the HA groups. The enhanced infiltration of HA LAG-3
-/-
 T cells into 
tumors depended on the co-administration of Cy, but in the lymph node, HA LAG-3
-/-
 T 
cells given without Cy were found to infiltrate in numbers equivalent to that of the HA 
cells with Cy and vaccine (Figure 2A-B). The adhesion molecules VLA-4, VLA-6, and 
CXCR3 have been found to be upregulated on HA TCR transgenic CD8
+
 T cells 
trafficking to the tumor, when given with Cy and 3T3neuGM vaccination 
50
. I 
hypothesized that these molecules would be upregulated to a greater degree on HA LAG-
3
-/-
 T cells compared to HA cells, accounting for their enhanced trafficking to the tumor 
microenvironment, and would occur as early as 3 days following adoptive transfer in the 
tumor-draining lymph nodes, preceding their arrival in the tumor.  For this study, I 
isolated lymphocytes from tumor-draining nodes in neu-N mice after treatment with 
vaccine plus or minus Cy and adoptive transfer of HA or HA LAG-3
-/-
 cells at days 3 and 
5 post-adoptive transfer and performed surface staining for CD8, Thy1.2 and 1 (VLA-4 
or VLA-6 beta chain), 4 (VLA-4 alpha chain) and 6 (VLA-6 alpha chain) integrins 
and CXCR3. There was a small but significant increase in the mean fluorescence 
intensity of 6 and 1 on day 5 after T cell transfer on HA LAG-3
-/-
 T cells given with 
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Cy and vaccine compared to HA cells (Figure 2C-D). There was also a trend towards 
increased level of 4 and 1 integrins on HA LAG-3
-/- 
cells on day 3 post-adoptive 




 T cells expressing 
CXCR3 on day 3 was increased among the HA cells with or without Cy compared to the 
same treatment group for HA LAG-3
-/-
 cells, while there was no significant difference in 




 cells are polyfunctional in the setting of Cy and vaccine  
Previous studies reported that FVB/N mice vaccinated against HER-2/neu 
develop polyfunctional T cells with the ability to produce multiple cytokines such as IL-
2, TNF, IFN, and Granzyme B, characteristic of a productive immune response, 
whereas the T cells induced in neu-N mice lack this ability 
50
.  Therefore, I characterized 
the cytokine profile of the HA T cell populations, with and without LAG-3 expression, 
transferred into tumor-bearing neu-N mice.  T cells were compared by intracellular 
cytokine staining (ICS) for production of the 4 cytokines and surface upregulation of 
CD107a and CD107b (LAMP-1 and LAMP-2), a marker of T cell lytic capability. neu-N 
mice were treated with vaccine alone and with the combination of vaccine and Cy to 
assess the dependence of cytokine production on Treg depletion as well as LAG-3
 
signaling and the interaction of the two treatments. It is evident from Figure 2A that 
without Cy, few HA LAG-3
-/- 
nor HA cells infiltrate into tumors in neu-N mice and as is 
seen Figure 3, both types of T cells fail to make abundant cytokines without the addition 
of Cy. However, comparisons made between HA T cells and HA LAG-3
-/-
 T cells 
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demonstrate that HA LAG-3
-/-
 cells produce significantly more IFN, TNF, IL-2, and 
have higher surface levels of CD107 (Figure 3A-C and E). There was also a trend 
towards increased Granzyme B production in HA LAG-3
-/- 
cells when given with Cy and 
vaccine (Figure 3D). In addition, vaccine alone-treated neu-N mice given HA LAG-3
-/-
 
cells have higher expression of CD107 than HA cells in mice given vaccine alone 




 T cells have enhanced 
production of each cytokine, I also analyzed each possible combination of cytokines to 
assess polyfunctionality. In Figure 3F, it is evident that many HA LAG-3
-/-
 cells in neu-
N mice given Cy and vaccine are capable of producing 4 to 5 cytokines, whereas most of 
HA cells in mice treated with Cy and vaccine produce 3-4 cytokines and the majority of 
either T cell type in mice treated with vaccine alone produce 0, 1, or 2 cytokines. The 
increase in effector cytokine secretion also correlated with upregulation of the 
transcription factor, Tbet, which is associated with cytotoxic CD8
+
 T cell function, in HA 
LAG-3
-/-
 T cells compared to HA T cells in mice treated with Cy and vaccine or vaccine 
alone (Figure 3G). Thus, LAG-3 deletion can enhance the effects of Cy given with 
3T3neuGM on adoptively transferred CD8
+
 T cells in a tolerant mouse model. 
 
Deletion of endogenous LAG-3
-/-
 enhances tumor clearance, but not T cell activation 
After confirming the CD8
+
 T cell intrinsic effects of LAG-3 in high avidity neu-
specific T cells in neu-N mice, I hypothesized there may be additional effects of LAG-3 
signaling in a tumor antigen tolerance model as LAG-3 is known to be expressed by 
many immune cell types. Additionally, there may be an interaction between LAG-3 
24 
 
signaling in adoptively transferred CD8
+
 T cells and in endogenous immune cells. neu-N 
mice were crossed to LAG-3
-/-
 mice backcrossed onto the FVB/N genetic background to 
generate neu-N mice with complete knockout of LAG-3. The ability of these mice to 
clear tumor was assessed with a tumor challenge experiment and compared with what has 
previously been published in neu-N mice. Without treatment, neu-N LAG-3
-/- 
mice 
developed tumors with slower kinetics than neu-N mice, although the majority of mice 
did develop tumors by 3 weeks after injection with NT2.5 cells (Figure 4A) 
55
.  Only 1 
out of 5 mice that received the neu-directed vaccine alone developed a tumor, compared 
to all neu-N mice that develop tumors with vaccine alone (Figure 4A) 
55
. Given this, it 
was hard to make comparisons between mice treated with Cy, vaccine, and an adoptive 
transfer of HA or HA LAG-3
-/-
 T cells, as no mice developed tumors in these groups, 
regardless of the presence of Cy or the dose of T cells given, unlike the neu-N mice 
(compare Figure 1 with 4A).  I was able to compare trafficking and cytokine responses of 
HA or HA LAG-3
-/-
 cells transferred into neu-N and neu-N LAG-3
-/- 
mice using ICS to 
assess differences in T cell activation in each mouse model. As seen before in the neu-N 
mice, HA LAG-3
-/-
 T cells had enhanced trafficking to the tumor compared to HA cells 
when given with Cy and vaccine (Figure 4B). HA LAG-3
-/-
 T cells in the neu-N mouse 
model had enhanced infiltration into NT2.5 tumors compared to HA LAG-3
-/-
 T cells in 
neu-N LAG-3
-/- 
mice. Surprisingly, adoptively transferred T cells were found in the 
highest numbers in the tumors of neu-N LAG-3
-/- 
mice treated with vaccine alone, 
increased in comparison to vaccine and HA–treated mice and close to the level of HA 
LAG-3
-/- 
T cells in Cy and vaccine-treated neu-N mice (Figure 4B). HA LAG-3
-/- 
T cells 
in Cy and vaccine-treated neu-N mice had the highest number of cytokine producing 
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cells, with significantly more TNF and CD107 expression than HA LAG-3
-/-
 T cells in Cy 
and vaccine-treated neu-N LAG-3
-/-
 mice, indicating that endogenous deletion of LAG-3 
did not synergize with CD8
+
 intrinsic deletion of LAG-3 to enhance cytokine production 
(Figure 4C-G). The only advantage in activation that T cells in Cy and vaccine-treated 
neu-N LAG-3
-/-
 mice appeared to have compared to T cells in similarly treated neu-N 
mice was in increased production of Granzyme B and this was not significant (Figure 
4G). For vaccine alone-treated mice, the only benefit of host LAG-3 deletion on 
adoptively transferred T cell activation was increased IFN production in HA LAG-3
-/- 
T 
cell-treated mice compared to the same T cell type and treatment group in neu-N mice 
(Figure 4C). Polyfunctionality analysis revealed that HA LAG-3
-/- 
T cells in Cy and 
vaccine-treated neu-N mice produced the most cytokines per cell, with many cells 
expressing 3-5 cytokines, compared to other treatment groups in both neu-N mice and 
neu-N LAG-3
-/- 
 mice (Figure 4H). HA LAG-3
-/- 
T cells in Cy and vaccine-treated neu-N 
LAG-3
-/- 
mice had an intermediate phenotype, similar to that of HA T cells in Cy and 
vaccine-treated neu-N mice and neu-N LAG-3
-/- 
mice or HA LAG-3
-/- 
T cells in vaccine 
alone-treated in neu-N mice and neu-N LAG-3
-/- 
mice. Overall, the data suggests there is 
not an additional benefit to LAG-3 deletion endogenously in terms of adoptively 
transferred high avidity CD8
+
 T cell cytokine production and tumor infiltration, and 
therefore, the enhanced tumor clearance seen in neu-N LAG-3
-/- 
mice cannot be 
accounted for by change in the function of adoptively transferred CD8
+






 T cell and APC activation are not enhanced in neu-N LAG-3
-/-
 mice 
 One hypothesis for the lack of enhanced anti-neu CD8
+
 T cell activation yet 
increased protection against tumor challenge is that neu-N LAG-3
-/-
 mice harbor 
endogenous CD8
+
 T cells that are less tolerant to neu than what has been observed in 
endogenous CD8
+
 T cells following vaccination in neu-N mice 
48
. To test this hypothesis, 
neu-N and neu-N LAG-3
-/-
 mice were given a dose of 5 x 10
4
 NT2.5 cells on day 0, 
followed by Cy on day 2 and vaccine on day 3, and harvested 12 days after vaccination to 
allow for activation of the endogenous T cell response. As has been shown in other 
models, LAG-3
-/-
 mice have increased numbers of total CD8
+
 T cells in the spleen 
(Figure 5A). However, inconsistent with data from previously published models 
regarding the effect of LAG-3 on CD8
+





 T cells per spleen in neu-N LAG-3
-/-
 mice compared to neu-
N mice (Figure 5B). Few mice overexpressing neu would be expected to respond to neu 
compared to wild type FVB/N mice which consistently develop an endogenous CD8
+
 
response, a population that makes up 1-2% of their total CD8
+
 T cells. Indeed this was 




mouse having a response 
equivalent to the vaccinated FVB/N controls, when IFN responses were shown on an 
individual basis (Figure 5C).  
While this experiment demonstrates that the difference in tumor control between 
neu-N and neu-N LAG-3
-/- 
mice is unlikely to result from CD8
+
 intrinsic effects of LAG-
3 on the endogenous CD8
+
 T cell population, it does not rule out another effector 
population responsible for control of neu-expressing tumors. LAG-3 is known to have 
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effects in dendritic cells, an important antigen presenting cell (APC) type, among other 
immune cell populations 
37
. I hypothesized that abrogation of LAG-3 signaling may 





cells. Alternatively, deletion of LAG-3 could result in less activated APCs which could 
explain the failure of CD8
+
 T cells to produce more effector cytokines in neu-N LAG-3
-/- 
mice. To test these hypotheses, I evaluated the ability of CD11c
+
 cells from neu-N and 
neu-N LAG-3
-/- 
mice to induce proliferation and cytokine secretion in naïve HA and HA 
LAG-3
-/- 
T cells. Four days following vaccination, vaccine-draining lymph nodes were 
removed from neu-N and neu-N LAG-3
-/- 
mice and subsequently isolated CD11c
+
 cells 
were cultured with CFSE-labeled CD8
+
 T cells for 5 or 7 days. The differences in 
dilution of CFSE dye were not dramatic but showed, most notably, that HA LAG-3
-/- 
T 
cells divided the most in culture, regardless of APC type, consistent with what has 
previously published about the effect of LAG-3 on T cell proliferation (Figure 5D). 
There were also slight differences between the two APC types, with the neu-N LAG-3
-/- 
-
derived APCs causing more T cell stimulation for both HA and HA LAG-3
-/- 
cells 
(Figure 5D). In contrast to proliferation, these trends between neu-N LAG-3
-/-
 and wild 
type neu-N dendritic cells did not correlate completely with respect to cytokine secretion 
from the same culture conditions. There was more IFN secretion from HA LAG-3
-/- 
cells 
but only in the T cells cultured with neu-N LAG-3
-/- 
APCs; IFN secretion was equivalent 
between HA LAG-3
-/- 
 and HA cells cultured with neu-N APCs
 
(Figure 5E). The reverse 





less IFN in T cells than neu-N APCs (Figure 5E). Overall, deletion of LAG-3 signaling 
had complex effects on both APC and T cell populations.  
 The enhanced proliferation but decreased T cell cytokine production driven by 
LAG-3
-/-
 APCs was further investigated through staining for the costimulatory molecules 
CD80, CD86 and CD40, and IL-12 expressed by CD11c
+
 cells in neu-N mice and neu-N 
LAG-3
-/-
 mice. Adoptive transfer of HA LAG-3
-/-
 T cells or HA T cells was also included 
in the comparisons to assess the effect of the absence or presence of LAG-3 on the 
transferred T cell on APCs, as cleaved LAG-3 from the surface of activated T cells can 
also be a source of soluble LAG-3. Vaccine-draining and tumor-draining lymph nodes 
harvested 7 days after vaccination were isolated and examined for upregulation of the co-
stimulatory molecules and IL-12 to assess the effect of the absence of LAG-3 on the APC 
population. There were not many consistent differences between APCs from neu-N LAG-
3
-/-
and neu-N mice receiving the same treatment. In the tumor-draining nodes, there were 
higher levels of CD80 expression in vaccinated neu-N versus neu-N LAG-3
-/-
 mice in the 
group that received HA LAG-3
-/-
 cells (Figure 5F). However, neu-N LAG-3
-/-
 mice had 




 cells than neu-N mice that 
received vaccine, with or without Cy, and HA LAG-3
-/-
 T cells. CD40 appeared to have 




 cells for some of the treatment groups 
and CD86 appeared to have decreased expression in the same mice, although neither of 
these trends was found to be significant. In the vaccine-draining nodes, although there 
were some differences between the APCs of mice receiving the two different T cell types, 
there were no significant differences observed between neu-N LAG-3
-/-
and neu-N host 
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APCs in the level of CD80, CD86, or CD40 or in IL-12, by percentage or number of 
cells. However, it is possible that vaccine-draining nodes examined at an earlier time 
point would have shown differences evident in the tumor-draining node at 7 days 
following vaccination. 
 
LAG-3 deletion in low avidity T cells does not enhance function in non-tolerant mice  
 I examined the effect of LAG-3 on low avidity cells (LA) in the model available 
at the time of experimentation, the FVB/N wild type mice, which do not express neu 
under the MMTV promoter, to confirm if deletion of LAG-3 can improve LA function in 
this model. It has been previously shown that LA cells secrete lower levels of cytokines 
than HA cells in both neu-N and FVB/N mice and fail to control tumors in neu-N mice, 
even when given with Cy and the 3T3neuGM vaccine 
50
. HA cells can clear tumors in 
FVB/N mice without Cy or 3T3neuGM but LA cells fail to completely control tumor 
growth without co-administration of vaccine 
50
.  I compared the ability of LA and LA 
LAG-3
-/-
 cells to control NT2.5 tumors in a tumor clearance assay in which FVB/N mice 
were given an adoptive transfer of 6 x 10
6
 LA or LA LAG-3
-/-
 cells without Cy or 
vaccine. 6 x 10
6
 HA cells, given as a control, demonstrated complete control of tumors 
within the duration of the study (45 days) (Figure 6A-B). All 3 FVB/N mice that 
received LA cells initially had tumors that grew with faster kinetics than mice given HA 
cells but eventually all tumors regressed; however, only 2 out of 4 mice receiving LA 
LAG-3
-/-
 cells had NT2.5 tumors that regressed (Figure 6A-B). All tumors in FVB/N 






 The ability of LA and LA LAG-3
-/-
 cells to infiltrate tumors and produce 
cytokines was also investigated in the FVB/N mice. Larger doses of tumors were given to 
ensure tumor growth for analysis of infiltrating cells and tumors were harvested 5 days 
after adoptive transfer. FVB/N mice were also given Cy and vaccine as this has been 
shown to result in optimal cytokine expression in LA cells 
50
. There was no significant 
difference in the number of cells that trafficked into NT2.5 tumors in FVB/N mice 
between the LA and LA LAG-3
-/-
-treated mice (Figure 6C). Additionally, there were no 
significant differences in the number of IFN, TNF and Granzyme B-producing CD8
+ 
T 
cells and there was a trend towards less cytokine-producing T cells in the mice receiving 
LA LAG-3
-/- 
cells compared to the LA-treated group (Figure 6C). Overall, LAG-3 
deletion in LA cells did not augment their function and may have actually decreased the 
function of LA cells in non-tolerant mice. It remains to be seen if LA LAG-3
-/-
 would 






 In this study of LAG-3 in a tolerant mouse model of breast cancer, LAG-3 was 
shown to have diverse and complex effects, perhaps resulting from the interaction of 
LAG-3 signaling in different cell types. First and most evident, LAG-3 had cell intrinsic 
effects on neu-specific CD8
+
 T cells. The ability to produce multiple cytokines 
simultaneously, known as polyfunctionality, is a hallmark of potent CD8
+ 
T cells able to 
clear viral infections, and is often defective in TIL 
63
. HA cells in FVB/N mice can 
produce multiple cytokines, but HA cells in tumor tolerant neu-N mice fail to fully 
function even in the presence of Treg depletion and vaccination 
50
. The augmentation of  
function in tumor antigen-specific CD8
+ 
T cells in terms of proliferation and cytokine 
production with blockade of LAG-3 signaling has been shown in other models and 
patient-derived T cells 
30,35
.  I hypothesized that the addition of a checkpoint inhibitor 
would enhance neu-specific CD8
+
 T cell function. Indeed, I observed increased HA cell 
expansion and tumor trafficking with LAG-3 deletion as well as greater control of 
tumors.  
 In our system, there was a requirement for Treg depletion with Cy as seen in 
Figures 1-3 for tumor control and polyfunctionality of HA T cells even in the setting of 
modulation of immune checkpoints and vaccination. Although increased CD8
+
 T cell 
proliferation and IFN production has been shown before in other mouse models when 
LAG-3 is blocked in CD8
+
 T cells, the increased TNF and IL-2 seen in our system with 
Cy and vaccine has not been shown before. Antibody blockade of LAG-3 alone (without 
co-blockade of PD-1) failed to upregulate cytokine production in patient TIL 
35
. There is 
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synergy observed with LAG-3 blockade in CD8
+
 T cells and vaccination against a tumor 
antigen with a Vaccinia viral vector and with dual antibody blockade of LAG-3 and PD-1 
in mouse tumor models 
30,34
. LAG-3 and PD-1 single knockout mice do not experience 




 (double knockout) mice; 
however, PD-1 antibody therapy has been shown to cause some autoimmune adverse 
effects in clinical trials 
34
.  There was no autoimmunity observed grossly in the mice 
receiving HA or LA LAG-3
-/- 
cells in my studies. The more subtle regulation of CD8
+
 T 
cell activation and function by LAG-3 may make it an ideal candidate for cancer 
treatment in terms of side effect profile, but only when paired with other forms of 
immunotherapy that serve to enhance the efficacy of LAG-3 blockade without inducing 
autoimmunity. 
 The role of LAG3 in restoring function of LA T cells was also explored with 
surprising results. Although it remains unclear how the function of LA cells would be 
altered in tolerant neu-N mice with deletion of LAG-3, there was no advantage to genetic 
deletion of LAG-3 in LA cells when transferred into wild type FVB/N mice in terms of 
tumor clearance or cytokine production. It is possible that no increased activation in 
terms of cytokine production was seen in the FVB/N mice as T cells transferred into wild 
type mice, without being subject to tolerizing mechanisms, may peak in their ability to 
produce cytokines. However, I did observe a decreased ability to control neu-expressing 
tumors; only 2 out of 4 LA LAG-3
-/- 
mice cleared tumors after 45 days versus all 3 LA-
treated mice in Figure 6B, demonstrating that deletion of LAG-3 in the LA cells does not 
seem to be beneficial. Unfortunately, I could not make direct comparisons with the HA 
cells as those experiments were done in neu-N mice only. It is interesting that the anti-
33 
 
tumor ability of LA cells did not increase with deletion of LAG-3 as it has been shown 
that low affinity CD8
+
 T cells have higher expression of checkpoint molecules including 
LAG-3, PD-1, and NKG2A than high affinity CD8
+
 T cells, correlating with their 
decreased function 
64
. Despite my findings’ inconsistency with the generally observed 
CD8-intrinsic effects of LAG-3, it is possible that LA T cells require blockade of more 
than one inhibitory signaling pathway, due to their pre-existing dysfunction and lower 
avidity for tumor antigen. This is relevant to cancer treatment as these cells with lower 
avidity and functional capability are similar to what is observed in patient TIL. However, 
for complete understanding of the different effects of LAG-3 in HA and LA cells, a 
comparison of the LA and LA LAG-3
-/-
 cells would need to be completed in neu-N mice.  
 The effect of LAG-3 deletion on CD8 function in a non-intrinsic manner was 
investigated by using neu-N LAG-3
-/-
 mice. This system of adoptively transferring HA 
and HA LAG-3 CD8
+
 T cells into neu-N and neu-N LAG-3
-/-
 mice revealed surprisingly 
complex effects of deleting LAG-3 globally. neu-N LAG-3
-/-
 mice were able to clear 
tumors with or without Cy in addition to vaccine and an adoptive transfer, suggesting that 
endogenous blockade of LAG-3 signaling resulted in enhanced T cell function. However, 
dual deletion of intrinsic and extrinsic LAG-3 signaling did not result in increased T cell 
tumor infiltration or polyfunctionality as had been expected. Thus, the effects of LAG-3 
deletion in CD8
+
 T cells may be countered by opposing CD8
+
 T cell-extrinsic effects as 
seen in the neu-N LAG-3
-/-
 mice, resulting in another anti-tumor cell population which 
becomes more activated, but also less activated adoptively-transferred cells. Based on 
cytokine assays of endogenous CD8
+
 T cells in vaccinated neu-N and neu-N LAG-3
-/- 
mice, this was not explained by enhanced endogenous CD8
+
 T cell function. 
34 
 
 Dendritic cells, potent activators of the T cell response, can become tolerogenic in 
the setting of tumors in mice and humans, downregulating the costimulatory molecules 
required for activation of T cells 
10
. In the neu-N mouse, it was demonstrated that low 
dose Paclitaxel could enhance the activation status of APCs and together with 
3T3neuGM vaccination, increased survival and tumor rejection through this mechanism 
65
. LAG-3 is known to have different effects on the APC population; in one study, LAG-3 
present on the surface of Tregs was shown to deliver an inhibitory signal through MHC II 
to APCs 
66
. Alternatively, a soluble LAG-3-Ig fusion protein has been given as an 
adjuvant and appears to increase the humoral and cell-mediated response through 
increased APC activation 
67,68
. Based on these controversial findings, the absence of 
LAG-3 endogenously may have either inhibitory or stimulatory effects on the APC 
population. The source of LAG-3 may not be of consequence as long as LAG-3 is present 
in the proximity of APCs, so I designed experiments to test different combinations of 
LAG-3 wild type and LAG-3
-/-
 APCs and T cells. In Figure 5, I demonstrated that while 
the combination of HA LAG-3
-/-
 cells with neu-N LAG-3
-/-
 APCs resulted in the highest 
T cell proliferative capacity, neu-N APCs activated more T cell cytokine production than 
the neu-N LAG-3
-/-
 APCs regardless of the T cell type, providing a partial explanation for 
the decreased cytokine expression seen in adoptively transferred T cells in the neu-N 
LAG-3
-/-
 mice. The expression of co-stimulatory molecules and IL-12 was equally 
divergent in that neu-N LAG-3
-/-
 APCs produced more IL-12, but had lower levels of 
CD80. The lack of a consistent phenotype failed to fully explain the differences in T cell 
function seen in these models.  
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 There could also be potential contributions from other cell types which I did not 
explore, including plasmacytoid DCs (pDCs) and Tregs, among others. pDCs are an 
abundant source of soluble LAG-3 which regulates their own homeostasis and can also 
effect T cell homeostasis independently of CD8-intrinsic LAG-3 control of homeostatic 
proliferation 
37
. Tregs are known to express LAG-3 and neu-N mice contain Tregs shown 
to inhibit adoptively transferred CD8
+
 T cells 
50
. Blockade of LAG-3 on Tregs can inhibit 





 cells, demonstrating that LAG-3 contributes to suppression 
function of Tregs 
36
. While I did not directly study this population, decreased Tregs or 
Treg function could be one explanation why the vaccine alone-treated neu-N LAG-3
-/-
 
mice have enhanced function of adoptively transferred HA LAG-3
-/-
 cells in terms of 
polyfunctionality and tumor infiltration as seen in Figure 4.  
 While using pre-isolated CD8
+ 
T cells for adoptive transfer into neu-N mice limits 
the knockout of LAG-3 to the CD8
+
 T cell, the caveat of the neu-N LAG-3
-/-
 mice is that 
the deletion of LAG-3 is not limited to a certain cell population. Thus, conditional 
knockouts of LAG-3 would need to be created in order to narrow down the effects of 
LAG-3 deletion in different cell populations on CD8
+
 T cell function and tumor 
immunity. Alternatively, reconstitution experiments in immunodeficient or irradiated 
mice may also be useful in addressing this question. While there are clearly some benefits 
to deletion of LAG-3 in high avidity antigen-specific CD8
+ 
T cells, it remains to be seen 
how expression of this molecule in other cell types interacts with T cells and therefore, 
how practical LAG-3 will be as a cancer therapeutic.  
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Figure 1. HA LAG-3
-/-
 cells control NT2.5 tumors at lower doses than HA cells when 
given with Cy and 3T3neuGM vaccine. Tumor growth curves for neu-N mice given 5 x 
10
4
 NT2.5 cells subcutaneously in the mammary fat pad on day -5 and (A) treated with 
Cy (100 mg/kg) on day -2, 3T3neuGM at day -1, and an adoptive transfer of the indicated 
dose of high avidity or high avidity LAG-3
-/-
 cells on day 0 or (B) treated with 
3T3neuGM on day -1 and adoptive transfer on day 0 (n = 2 mice per treatment group and 
dose).   
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Figure 2. HA LAG-3
-/-
 cells have enhanced tumor infiltration compared to HA cells 
in the presence of Cy and vaccine. (A-B) NT2.5 tumors (A) and tumor-draining lymph 
nodes (B) of mice treated with vaccine or with Cy and vaccine were harvested 5 days 
post-adoptive transfer of HA and HA LAG-3
-/-
 T cells. The number of tumor-infiltrating 
lymphocytes was calculated based on total cells per mg of tumor or per lymph node and 




.  (C-F) Tumor-draining nodes were 
removed from neu-N mice 3 or 5 days following adoptive transfer of T cells and cells 
were stained with antibodies to the following surface proteins: (C) 6 integrin, (D) 1 
integrin, (E) 4 integrin, and (F) CXCR3.  Mean fluorescence intensity was measured for 




 expressing the surface 









Figure 3. Cy, vaccine, and an adoptive transfer of HA LAG-3
-/- 
cells result in 
polyfunctional T cells infiltrating tumors in neu-N mice. NT2.5 tumors from neu-N 
mice treated with vaccine with or without Cy were harvested 5 days post-adoptive 
transfer of HA or HA LAG-3
-/-
 cells and adoptively transferred cells were identified by 





for 5 hours. The percentage of cells expressing each cytokine in response to RNEU
420-429 
is normalized for each mouse’s response to NP
118-126





 cells in each treatment group expressing the cytokine was calculated from 
the percentage of expressing cells and a total count of tumor-infiltrating lymphocytes.  
(F) Each pie chart shows the average percent of total cells expressing each possible 
combination of 0-5 cytokines and/or CD107a/b in response to RNEU
420-429 
for the given 
treatment group. Red corresponds to expression of all 5 cytokines and purple corresponds 
to expression of 0 cytokines, with values in between representing particular 
combinations. Treatment group is denoted by: CVL: Cy, Vaccine, HA LAG-3
-/-
 cells; 
VL: Vaccine, HA LAG-3
-/-
 cells; CVH: Cy, Vaccine, HA cells; VH: Vaccine, HA cells. 




 T cells expressing Tbet demonstrates that HA LAG-3
-/-
 
cells have a significantly higher percentage of Tbet expression than HA cells, with or 









Figure 4. Endogenous deletion of LAG-3 signaling enhances tumor clearance but 
not activation of adoptively transferred HA cells. (A) neu-N LAG-3
-/-
 mice were 
challenged with NT2.5 cells and given either no treatment, vaccine alone, or vaccine and 
Cy with varying doses of HA or HA LAG-3
-/- 
T cells. Tumors failed to grow in mice 
given any dose of T cells with vaccine and with or without Cy. Treatment with vaccine 
resulted in statistically significant less tumor growth compared to untreated mice (p = 
0.017, n = 2 mice per treatment group for each dose of T cells, 5-6 mice for all other 






were compared in mice treated with vaccine, plus or minus Cy, 
and an adoptive transfer of HA or HA LAG-3
-/- 
T cells. In (B-G), the number of cells per 
mg tumor expressing each cytokine was calculated from the percentage of cells 
expressing each cytokine and the total of infiltrating lymphocytes per mg of tumor for 
each mouse. In (H), each pie chart shows the average percent of total cells expressing 
each possible combination of 0-5 cytokines and/or CD107a/b in response to the RNEU
420-
429 
for the given treatment group. Red corresponds to expression of all 5 cytokines and 
purple corresponds to expression of 0 cytokines, with values in between representing 
particular combinations. Treatment group is denoted first by host mouse and then by 
treatment type: CVL: Cy, Vaccine, HA LAG-3
-/- 
cells; VL: Vaccine, HA LAG-3
-/- 
cells; 










Figure 5. neu-N LAG-3
-/- 
do not harbor more activated anti-neu T cells, despite 
differences in APC activation. (A-C) neu-N and neu-N LAG-3
-/-
 mice were assessed for 
the endogenous anti-neu CD8
+
 T cell response after vaccination. (A) neu-N LAG-3
-/-
 
mice have increased numbers of CD8
+
 T cells per spleen. (B) The average number of 
cells per spleen responding to RNEU
420-429 
over background (irrelevant peptide, NP
118-126
) 
for neu-N and neu-N LAG-3
-/-
 mice does not significantly differ. (C) The individual IFN 
response to RNEU
420-429 
(compared to negative control NP
118-126
) is shown for all 
vaccinated neu-N and neu-N LAG-3
-/-
 mice (n = 9 per group, *p<0.05). (D-E) CD11c
+
 
cells from 9 vaccinated neu-N and neu-N LAG-3
-/-
 mice each per group were incubated 
with CFSE-labeled CD8
+
 T cells from HA and HA LAG-3
-/-
 mice. (D) CFSE dilution on 
day 7 is shown as a measure of proliferation. The percent of cells that are divided is 
calculated from the percentages of total cells found in CFSE peaks 3-6. (E) IFN 
expression was measured on day 5 from 2 wells of each combination of CD8
+
 T cells and 
APCs.  APCs derived from vaccinated neu-N mice resulted in more IFN-producing T 
cells than APCs from neu-N x LAG-3
-/-





 cells from tumor-draining lymph nodes (F) and vaccine-draining nodes 
(G) were stained for co-stimulatory surface markers and IL-12 one week after vaccination 
of neu-N and neu-N x LAG-3
-/-
, that also received adoptive transfer of T cells and in 
















deletion in LA cells does not augment their function in FVB/N 
tumor-bearing mice. (A-B) Growth curves of mean tumor size (A) and individual 
mouse tumor growth curves (B) for FVB/N mice given 2 x 10
6
 NT2.5 tumor cells and left 
untreated or treated with 6 x 10
6
 HA, LA, or LA LAG-3
-/- 
cells (n=3-4 per treatment 
group.) (C) Number of cells infiltrating NT2.5 tumors and producing each cytokine in 
FVB/N mice given 5x 10
6
 NT2.5 cells and Cy, vaccine, and an adoptive transfer of 6 x 
10
6
 LA or LA LAG-3
-/- 
cells. There was no significant difference between the two groups 






Chapter 3: A LISTERIA MONOCYTOGENES VACCINE TARGETING 
MUTATED KRAS, AN EARLY GENETIC EVENT IN PANCREAS CANCER 
DEVELOPMENT, PREVENTS PRE-MALIGNANT TUMOR PROGRESSION IN 




Pancreatic ductal adenocarcinoma (PDA) is clinically difficult to treat due to its 
late detection and resistance to conventional therapies. However, recent studies suggest 
that the process of PDA development from tumor initiation to metastasis formation 
requires years to decades for completion, providing a window of opportunity for 
prevention and treatment during the stage when pre-cancerous lesions, known as 




One potential treatment 
approach involves the development of immunization strategies that target the driver 
genes, early genetic changes that initiate pre-malignant lesion formation. 
Immune tolerance mechanisms to self-antigens are significant barriers to anti-
tumor immunotherapy, especially once PDA has developed 
70-72
. Treatments that break or 
bypass tolerance and induce a specific anti-tumor immune response in the periphery are 
still relatively ineffective due to the local immunosuppressive mechanisms at the site of 
the tumor. While LAG-3 is one checkpoint molecule upregulated on tumor antigen-
specific T cells, the site of tumor development in pancreatic cancer harbors many 
additional immunosuppressive signals and cells populations which include Tregs, 
tolerogenic antigen presenting cells (APCs) and myeloid derived suppressor cells 
47 
 
(MDSC), and immunosuppressive cytokines (i.e. IL-4, IL-10, TGF-) 
10,73-75
. Of these 
barriers to effective cancer immunotherapy, Tregs and MDSC, have been shown to be 







 MDSC have been shown to inhibit protective CD8
+
 T cell 
responses and to promote PDA growth 
77-79
. Treatments that deplete or inhibit the activity 
of Tregs, such as low dose Cyclophosphamide (Cy) and anti-CD25 inhibitory monoclonal 
antibodies, have enhanced T cell activation by antigen-targeted vaccine approaches 
against many cancers including PDA in numerous pre-clinical and clinical studies 
16,78
.  
Both Cy and the murine anti-CD25 antibody, PC61, appear to enhance T cell trafficking 
into tumors, allowing tumor eradication, by increasing the effector T cell to Treg ratio 
within the tumor and tumor draining lymph nodes, key sites of Treg accumulation and 
activation in mice 
50,75,78
.   
Genetically engineered mice that mimic the genetic induction and progression of 
tumors at the natural organ site allow for the study of the immune response to cancer and 
its precursor lesions within the tissue specific microenvironment and in the context of 
natural regulatory mechanisms that result in tolerance to the initiating oncogene products 
51






;Pdx-1-Cre mice are 
genetically programmed to mimic the progression from normal tissue through all stages 




;Pdx-1-Cre mice progress 
onto fully developed PDA which recapitulates human PDA in both genetic and 
histological features 
80,81
.  This mouse model also possesses the advantage of mimicking 
the local immunosuppressive environment at the site of tumor development, including the 
48 
 
desmoplastic response which occurs in the stroma of pancreatic cancer as a response to 
tumor development. While transplantable tumor models such as the Panc02 mouse tumor 
model which has been used to study pancreatic cancer and the HER2/neu-expressing 
tumor line NT2.5 which has been used to study breast are useful for studying the 





Cre mouse model has the advantage of re-creating the microenvironment in the natural 








;Pdx-1-Cre mice have been reported to exhibit Treg 
infiltration of late stage PanINs and PDA 
51
.  Here we report for the first time the 
observation that Treg infiltration occurs as early as PanIN stage 1. In addition, we show 
that immunization with a Listeria monocytogenes (LM) vaccine genetically modified to 
express the driver Kras
G12D
 gene product (LM-Kras) induces a systemic CD8
+
 T cell 
response directed against the oncogenic Kras protein at all stages of pre-malignant lesion 
formation. However, LM-Kras vaccination given together with Treg depletion at the time 
of PanIN 1 slows progression to PDA whereas the combination fails to slow progression 
when given at the time of PanIN stage 2-3 development.  Importantly, the cytokine milieu 
is directed in favor of T cells secreting IFN and IL-17 that is associated with increased 
effector CD8
+
 T cell infiltration and prevention of early PanIN progression. Combination 




 cells secreting 
immunostimulatory cytokines that have lost the ability to suppress CD8
+
 T cells. These 
49 
 





Materials and Methods 





; and Pdx-1-Cre strains on a 
mixed 129/SvJae/C57BL/6 background, were a gift from Dr. David Tuveson (Cold 
Spring Harbor Laboratory, Cold Spring, NY). These mice were backcrossed to the 














;Pdx-1-Cre (KPC). Genotyping was performed 
according to gene assays as previously described and genotyping services were provided 
by Transnetyx, Inc. 
80,81
. Animals were kept in pathogen-free conditions and treated in 
accordance with institutional and American Association of Laboratory Animal 
Committee approved policies. All animal studies were approved by the Institutional 
Animal Care and Use Committee of the Johns Hopkins University. 
 
Patients and tumor samples.  
 Mesothelioma biopsies were collected from a subject on study #ADU-CL-02, a 
phase I study evaluating the safety and induction of immune response of CRS-207, a LM 
vaccine targeting mesothelin, in combination with chemotherapy in patients with 
malignant pleural mesothelioma 
82
. Patients signed an informed consent after approval of 
the study by the institutional review board. 
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Listeria monocytogenes (LM) construct   
 LM strains were derived from the DP-L4056 strain that had been deleted for both 
the actA and inlB open reading frames as described 
83
. The double 12 ras expression 
cassette was designed in silico to fuse the 25 amino acids of both V and D activating 
mutations (at position 12) in a synthetic gene codon optimized for expression in LM with 
Gene Designer software and synthesized (DNA2.0, Menlo Park, CA) 
84
.  The synthetic 
gene was cloned downstream of the actA promoter in a derivative of the vector pPL2 and 
stably integrated at the tRNA
Arg
 locus of the bacterial chromosome as described 
previously 
83
. All molecular constructs were confirmed by DNA sequencing. A schematic 
of the antigen construct is shown in Figure 1A.  
 
LM Vaccine Preparation and Injection  
 Experimental stocks were prepared by growing bacteria to early stationary phase, 
washing in PBS, resuspending at approximately 1x10
10
 cfu/ml in PBS plus 10% glycerol, 
and freezing aliquots at -80 °C for later use. 5x10
5
 cfu in 0.2 ml PBS were injected via 
the tail vein based on dose titrations for each batch of vaccine. 
 
GM-CSF-secreting tumor cell vaccine  
GM-CSF-secreting cell line B78H1-GM was grown and prepared as previously 
described 
78
. The KPC tumor cell line was created from a spontaneously arising KPC 
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mouse tumor by digesting the diced tumor in RPMI 1640 plus 5% FBS, collagenase and 
hyaluronidase at 37°C for 1 hour, passing through a 100 m strainer to obtain a single 
cell suspension, and culturing the cells in RPMI 1640 media containing 20% FBS, 1% L-
glutamine, 1% MEM NEAA, 1% sodium pyruvate, 0.5% penicillin/streptomycin, and 0.2 
units/mL insulin.  Non-adherent cells were aspirated off the culture flask and epithelial 
cells were purified from fibroblasts by serial trypsinization. The vaccine was prepared by 
washing cells twice in PBS, mixing cells at a 1:1 ratio, and irradiating at 50 Gy. 4-6 week 
old KPC mice were injected with 3 x 10
6
 cells of each line in three injections of 0.1 ml 
subcutaneously to one forelimb and both hindlimbs. 
 
Survival Experiments  
 The anti-CD25 depleting monoclonal antibody, PC61 (ATCC), was produced 




Cyclophosphamide (Cytoxan, Cy, 
Bristol Myers Squibb) was reconstituted in sterile water at 20 mg/ml and then diluted in 
sterile PBS. KPC mice age 4-6 weeks or 8-14 weeks were treated with intraperitoneal 
(IP) PC61 (50 g per mouse) and Cy (100 mg/kg), one day prior to vaccine injection as 
per experimental design. This regimen was repeated according to group assignment every 
4 weeks and survival monitored weekly. Moribund animals were euthanized in 
accordance with institutional policies. 
 
Splenocyte intracellular cytokine assays  
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 Peptides were synthesized at >95%
 
purity by the Peptide Synthesis Facility (Johns 
Hopkins,
 
Baltimore, MD). 7 days after vaccination, mice were sacrificed and splenocytes 
were harvested. Splenocytes were briefly treated with ACK Lysis Buffer (Quality 
Biological Inc.) for red blood cell lysis. CD8
+
 T cells were negatively selected using the 
Dynabeads Mouse Untouched CD8 Cells (Invitrogen), and then incubated for 5 hours 
with T2K
b
 cells pulsed with the indicated peptides in the presence of GolgiStop (BD 
Biosciences) as per the manufacturer’s instructions. Following incubation, cells were 
harvested, stained with CD3-APC (145-2C11), CD8-PerCP (53-6.7, BD Pharmingen) and 
then permeabilized with CytoFix Fixation Buffer, washed with Perm/Wash Buffer (BD 
Biosciences), and stained with interferon-gamma (IFN)-PE (XMG1.2, BD Pharmingen). 
To stain for intranuclear transcription factors, the PE anti-mouse/rat Foxp3 staining set 
(eBioscience) was used to fix, permeabilize, and stain cells with Foxp3-PE (FJK-16s, 
eBioscience) as per the manufacturer’s instructions. Data was collected using a 
FACSCalibur and CellQuest Pro (BD Biosciences) and analyzed using Flowjo software 
(Treestar, Inc.). 
 
Isolation of pancreatic infiltrating leukocytes and intracellular cytokine assays  
 Isolated pancreata were weighed, diced, and incubated with collagenase (1 mg/ml, 
Sigma) and hyaluronidase (25 mg/L, Sigma) for 30 minutes at 37
o
C followed by passage 
through a 40 m nylon cell strainer. Single cell suspensions were stained with CD3-APC-
Cy7 (145-2C11, BioLegend), CD8-Pacific Blue (53-6.7, BD Pharmingen), CD4-Pacific 
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Orange (RM4-5, Invitrogen Molecular Probes) or CD4-PerCP (GK1.5, Biolegend), 
CD44-Alexa Fluor (AF) 700 (IM7, BD Pharmingen), and CD62L-AF647 (MEL-14, 
Biolegend). For cytokine assays, lymphocytes from pancreata were isolated as above and 
purified by Percoll gradient (GE Healthcare). Lymphocytes were stimulated with anti-
CD3/CD28 beads (Invitrogen Dynal AS) overnight at 37°C followed by a 5 hour 
incubation with Golgistop, fixed and permeabilized, and stained with IFN-AF700 
(XMG1.2, BD Pharmingen), TNF-AF488 (MP6-XT22, BD Pharmingen), IL-17-AF647 
(eBio17B7, eBioscience), Foxp3-V450 (MF23, BD Horizon), Tbet-PE-Cy7 (4B10, 
eBioscience) and RORt-PE (Q31-378, BD Pharmingen).  For T cell cytokine analysis, 
lymphocytes from up to 3 mouse pancreata were pooled and stained as one flow 
cytometry sample due to small cell numbers. In assays for IL-17, IMDM (Gibco, Life 
Technologies Corporation) supplemented with 5% FCS, 1% L-glutamine, 1% 
penicillin/streptomycin, and 5 x 10
-5
 M -mercaptoethanol was used for cell culture. For 
myeloid cell stains, the Percoll-purified cells were stained with CD45-APC-Cy7 (30-F11, 
BD Pharmingen), CD11b-PE-TexasRed (M1/70.15, Invitrogen), F4/80-PE-Cy7 (BM8, 
eBioscience), Gr-1-AF700 (RB6-8C5, BD Pharmingen) or Ly6G-V450 (1A8, BD 
Horizon) and Ly6C-PerCP-Cy5.5 (HK1.4, Ebioscience) and following 
fixation/permeabilization, IL-12-APC (C15.6, BD Pharmingen) and IL-10-V450 (JES5-
16E3, BD Horizon). Prior to staining, all samples were incubated with Live/Dead Fixable 
Dead Cell Stain Kit (Invitrogen Molecular Probes) to assess cell viability and anti-
CD16/CD32 antibody (Fc Block, BD Biosciences).  Flow cytometry was performed 
using an LSR II and analyzed using FACSDiva software (BD Biosciences).  
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CD8, IL-17, and Ly6G Depletion Assays  
 The CD8-depleting antibody 2.43 (500 mg intraperitoneal injection) 
48
 or control 
rat IgG (Jackson ImmunoResearch Inc.) was given every other day for one week prior to 
vaccine treatment, followed by twice weekly injections throughout the 5 week course of 
two cycles of therapy with PC61, Cy, and LM-Kras. CD8 depletion was verified 
routinely throughout the study by flow cytometry. Anti-IL-17 antibody, a gift from Dr. 
Jerry Niederkorn 
85
, or rat IgG control was given in a 200 g dose twice a week for the 
first week of treatment, followed by 100 g twice weekly treatments for the duration of a 
five week cycle of treatment with LM-Kras and PC61/Cy four weeks apart, with harvest 
one week after the second vaccine. Anti-Ly6G antibody, 1A8, (Bio X Cell) was 
administered at a 0.5 mg dose 3 times in the first week of the experiment, followed by 
0.25 mg twice a week for the following 4 weeks.  
 
Immunohistochemistry (IHC)  
 Immunohistochemistry was carried out according to standard protocols 
86
. Briefly, 
for CD4 and CD8 stains, pancreata were frozen in Tissue-Tek OCT (Sakura Finetek 
USA, Inc) with liquid nitrogen and cut in 5 m sections using a cryostat, followed by -
20°C acetone fixation. Sections were incubated with 5 g/ml primary antibodies to CD4 
(H129.19), CD8 (53-6.7), or isotype control (R35-95) (BD Pharmingen) for 1 hour and 
with biotin-conjugated secondary antibody (G28-5, BD Pharmingen) for thirty minutes. 
For Foxp3, F4/80 and Ly6G staining, pancreata were fixed in 10% neutral buffered 
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formalin (VWR International), embedded in paraffin and sectioned by the Johns Hopkins 
Medical Institutions Reference Histology Laboratory. Tissue sections were subjected to 
antigen retrieval by steam heating in Citra antigen retrieval solution (BioGenex) or for 
F4/80 antibody, proteinase K (Dako). The following antibodies were used: anti-F4/80 
(Serotec, C1:A3-1, 1:100), anti-Ly6G (BD Bioscience, 1A8, 1:2000) and the 
corresponding biotinylated secondary antibodies (1:200, Vector Laboratories). For 
Foxp3, slides were stained by the Johns Hopkins IHC laboratory using the Envision 
FLEX, high pH system (Dako) for automated Dako platforms with a 1:100 dilution of 
anti-mouse Foxp3 antibody (Abbiotec, LLC.). For patient samples, sections were stained 
with anti-CD3 (2GV6, Ventana Medical Systems, Inc.) using ultraView Detection 
(Ventana Medical Systems, Inc.) according to standard Ventana protocols in the Johns 
Hopkins University Immunopathology Lab. For RORt (6F3.1, EMD Millipore 
Corporation), antigen retrieval was performed with EDTA at 95°C for 20 min and slides 
were stained using Leica auto stainers and Bond Polymer Refine Detection (Leica 
Microsystems Inc., Buffalo Grove, IL). All slides were imaged using an Eos Rebel T2i 
camera (Canon U.S.A.) and Eclipse TS100 microscope (Nikon Inc.).  
 
Histological analysis of pancreatic lesions   
 Pancreata were formalin fixed and paraffin embedded, cut at 4 m thickness and 
stained using routine H&E staining protocols by the Johns Hopkins Reference Histology 
Lab and Tissue Microarray Lab. For analysis of vaccine and Treg depletion effect(s), 
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slides from each mouse pancreas were characterized based on number of each PanIN 
stage or PDA and graded based on highest stage PanIN (or PDA) present. For the CD8 
depletion and IL-17 depletion studies, the Cavalieri estimator method was employed to 
estimate PanIN or PDA volumes present in the pancreata 
87
. Two H&E-stained sections 
per pancreas spaced 400 microns apart were digitally scanned at 20x magnification 
(0.498 micrometers per pixel) using a ScanScope CS (Aperio, Inc., San Diego, CA).  The 
whole slide images (WSIs) were then analyzed using the Cavalieri estimator 
implemented in custom Java software. Briefly, a point counting grid with a grid spacing 
of 75 micrometers was applied to each WSI. Intersection points that fell on each of all the 
following histologic features were counted: tissue, ADM, PanIN-1, PanIN-2, PanIN-3, 
and PDA and the percent tissue occupied by each type was calculated for each WSI. This 
software can be downloaded at https://bitbucket.org/tcornish/point-counting. 
 
Suppression Assay, Cytokine Array, and Co-culture Conditions  
 Naïve CD8
+
 T cells were isolated from spleens of C57Bl/6 mice and labeled with 






 cells were isolated from the pancreas of 
KPC mice and stained as previously stated, followed by fluorescence-assisted cell sorting 






 population using a FACSAria II (BD Biosciences). 
Gr-1
+
 cells were incubated in a 1:1 ratio with CD8
+
 T cells for 72 hours in the presence of 
Dynabeads Mouse T-Activator CD3/CD28 (Invitrogen) in HL-1 media (Lonza) for the 
suppression assay and in IMDM for the ICS.  For the ICS of IL-17, those wells also 
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contained 0.02 g/ml TGF and IL-6 (Shenandoah Biotechnology, Inc.) and 10 g/ml 
anti-IL4 and anti-IFN (11B.11 and XMG1.2, Bio X Cell) for 72 hours. For the cytokine 
array, the pancreata of mice in a treatment group were pooled, Gr-1
+
 cells were sorted 
with FACS and lysed according to instructions, and lysate was blotted with the Mouse 
Cytokine Antibody Array, Panel A (R & D Systems).  The resulting dot blot was scanned 
and analyzed using VisionWorks LS (UVP, LLC) to calculate density per pixel. The 





Statistical analysis  
 Statistical significance was analyzed using GraphPad Prism (GraphPad Software, 
Inc.) and assessed using a two-tailed student T test. Welch correction was used when the 
variance was assumed to be unequal. For survival analysis, Log-rank (Mantel-Cox) test 
was used.  For data included in the suppression assay, two experiments were normalized 
to a scale based on third experiment to account for variation of baseline proliferation 
between assays. Significance was defined as p<0.05. All experiments were repeated three 







LM-Kras induces systemic CD8
+










transgenic mouse models in which the pancreas is genetically programmed to develop 
pre-malignant PanINs prior to malignant PDA provides the opportunity to develop 
vaccine strategies that can be employed at an early stage of cancer development when 
fewer mechanisms of immune tolerance would be expected to be at play.  Mutant Kras 
was chosen as a target for immunotherapy because it is the most prevalent and earliest 
oncogene known to be involved in human PDA development 
88
. The bacterial vector, 
LM, was selected to target Kras since LM vaccines have been shown to be efficacious in 
multiple preclinical models of infectious disease and cancer 
89-91
.  In addition, a safe and 
bioactive dose was recently reported for the treatment of patients with PDA 
82
. LM 
vaccines directly infect APCs (dendritic cells and macrophages) and LM-expressed 
antigens are presented on both MHC class I and class II molecules due to the natural 
lifecycle of LM, which after initial entry into APCs via the phagosome, replicates in the 
cytosol 
89
. In addition, inflammatory cytokines produced by infected APCs foster a Th1 
immune response favorable to anti-tumor immunity 
91
.  I therefore employed this model 
to test the hypothesis that an LM vaccine expressing mutated Kras
G12D





 T cell responses capable of slowing PanIN progression.  I 
used an attenuated LM strain deficient in the virulence factors ActA and InlB that is 
being developed clinically for treating patients with PDA and that was further modified 
60 
 
with a vector designed to express and secrete a portion of the Kras protein encompassing 
the G12D mutation (Figure 7A) 
82,92
.   
The LM-Kras vaccine was first tested for the ability to induce CD8
+
 T cell 
reactivity against the Kras
G12D
 target. To accomplish this, the specific 9 amino acid (9-
mer) peptides presented by the MHC I allele, H-2K
b
, expressed by transgenic mice, were 
identified using a previously described strategy that screens overlapping peptides for 
recognition by activated immunized lymphocytes using an intracellular cytokine 
secretion assay (ICS) (Figure 7B) 
61
. It was confirmed that vaccinated non-tolerant, 
MHC-matched mice harbor significant numbers of CD8
+
 T cells that secrete IFN in 
response to multiple mutant Kras epitopes (Kras B-G) in contrast to the control 
tyrosinase-related protein 2 (Trp2) epitope which also binds the MHC I K
b
 allele (Figure 
7C).  I next evaluated whether the LM-Kras vaccine can induce similar Kras-specific T 
cells in KC mice that do express the Kras protein mutated at position 12. KC mice 
vaccinated with the same LM-Kras vaccine showed a similar level of vaccine induced 
Kras-specific IFN CD8
+ 
T cell responses as vaccinated parental mice (Figure 7D).  
Similar responses were also seen in KPC mice (Figure 7E). These responses peaked at 
day 7 post-vaccination and declined by day 14 post-vaccination, the kinetics of which are 
similar to what is observed for LM-induced CD8
+
 T cell responses specific for other 




 T cell responses were not detected in 
unvaccinated mice suggesting that the mutation itself is not naturally immunogenic 
(Figure 7D). Surprisingly, these studies failed to identify differences in the magnitude of 
Kras-specific CD8
+
 T cell responses in the non-tolerant parental versus the transgenic 
61 
 
mice expressing the Kras
G12D
 mutation (Figure 7F). Thus, these data demonstrate that the 
LM-Kras vaccine can induce a sizable systemic CD8
+ 
T cell response against mutant 
Kras in both parental and potentially tolerant KC and KPC mice.  
 
Inhibition of PanIN progression requires both Treg depletion and LM-Kras 
The next question was whether these Kras-specific T cell responses in Kras-
mutated mice correlated with a delay in PanIN development and with prolonged survival.  





further evaluation of the kinetics of Treg infiltration, it was found that Foxp3
+
 cells are an 
early inflammatory change, present even at the time of the earliest stage of PanIN 
development, PanIN 1, and continue to increase with progression to malignancy (Figure 
8A). While both an anti-IL2R (CD25) monoclonal antibody and low dose 
cyclophosphamide (Cy) have been shown to deplete Tregs and improve survival in mice 
and patients, a combination of the murine anti-CD25 antibody, PC61, and Cy, resulted in 
the most complete depletion of Tregs in one PDA mouse model 
16,55,78
. As shown in other 
models, the combination of Treg-depleting agents given with vaccine resulted in a 




 T cells when compared to vaccine alone-
treated mice (Figure 8B-C). 
Therefore, a combination of PC61 (50 g) and Cy (100 mg/kg) given 1 day prior 
to vaccination was used to test the ability of LM-Kras given alone or with Treg depletion 
to inhibit tumors and prolong survival. The KPC rather than KC mice were used for this 
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experiment because the Trp53
R172H/+
 mutation is required for development of cancers at a 
predictable rate, which facilitates survival analysis. Two age groups were evaluated for 
survival, mice less than 2 months of age (low grade PanINs predominate), and mice older 
than 2 months of age (high grade PanINs predominate), to determine the effects of the 
vaccine relative to the degree of PanIN development at the time of init ial vaccination. 
Neither the LM-Kras vaccine alone nor the Treg-depleting agents (PC61 plus Cy) given 
alone affected survival when treatment was given to either age group.  However, 
combination therapy with the LM-Kras vaccine and Treg depletion with PC61 and Cy 
conferred a significant survival advantage to animals given treatment early, at the time of 
PanIN 1 development, but not to mice beginning treatment at the time of later stage 
PanIN 2 and 3’s (Figure 8D-E). These data provide evidence that Treg depletion 
enhances a vaccine’s ability to improve survival of mice treated at early stages of PanIN 
development, but not when treatment is initiated at later stages of PanIN development. 
Furthermore, the failure of LM-Kras and Treg depletion to delay PanIN progression in 
mice with later stage PanINs was not due to poor antigen-specific CD8
+
 T cell generation 
as systemic CD8
+
 T cell responses to LM-Kras did not significantly differ between 4-6 
week and 8-12 week old KPC mice (Figure 8F). 
To confirm that the combination of vaccine and Treg depletion was slowing 
PanIN progression, similarly designed experiments were conducted to perform 
histological analyses of the pancreas of mice beginning treatment at less than 2 months 
old using the same treatment groups as in Figure 8D and harvested after two cycles of 
treatment.  Mice given LM-Kras in combination with PC61 and Cy showed fewer late 
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stage PanINs and fewer occurrences of PDA (Figure 8G). Thus, at 5 weeks following 
initiation of immunotherapy, the overall lower stage of PDA development in mice treated 
with combination therapy is consistent with improved survival seen in Figure 8D.   
 
Combination immunotherapy alters local Treg to effector T cell ratio 
 I hypothesized the vaccine enhancing effects of PC61 and Cy were mediated 
through the enhanced induction of Kras-specific CD8
+
 T cell responses.  KPC mice with 
early stage PanINs were vaccinated at 4-6 weeks old and again one month later, with or 
without PC61/Cy pretreatment. Splenocytes were isolated and analyzed for IFN 
production in response to one of the mutated Kras peptides, KrasF, by ICS one week after 
the second vaccination. The response to the ovalbumin H-2K
b
-binding peptide, 
SIINFEKL (Ova), was also assessed since the LM-Kras construct contains this 
immunogenic positive control peptide to confirm vaccine potency. Interestingly, 
administration of PC61/Cy one day prior to LM-Kras vaccination decreased the systemic 
response to KrasF peptide when compared to LM-Kras vaccination alone as measured by 
percent of splenic CD8
+
 T cells producing IFN (Figure 9A).  In contrast, there was no 
significant difference between splenocyte CD8
+
 T cell responses measured against Ova 
between LM-Kras and PC61/Cy versus LM-Kras alone (Figure 9A).  While the total 
numbers of CD8
+
 T cells responding to either Ova or KrasF decreased with combination 
therapy compared to LM-Kras alone, this was not statistically significant and was not as 
profound for Ova as it was for KrasF, indicating that this was not solely due to the non-
64 
 
antigen-specific deletion of T cells by PC61 and Cy (Figure 9A). Furthermore, the 
percentage and total number of splenic CD4
+
 T cells from the same mice that produced 
IFN in response to non-antigen specific activation was not altered by PC61 and Cy 
(Kras peptides were not available for CD4
+
 T cells) (Figure 9B).  
 Both PC61 and Cy deplete Tregs, which can inhibit the activation and trafficking 
of vaccine-induced effector T cells, systemically and within tumors and tumor draining 
lymph nodes 
93-95
. Analysis of the CD4
+
 T cell populations by flow cytometry 









 T cells in the pancreas-draining lymph nodes of mice with early stage 
PanINs receiving PC61 and Cy plus the LM-Kras vaccine when compared to vaccine 




 T cells within the 
pancreas at this time point by flow cytometric staining did not achieve statistical 
significance (Figure 9C), decreased Tregs were evident by IHC staining for Foxp3 in 
pancreata from mice treated with PC61 and Cy plus LM-Kras (Figure 9D).  
 Increasing evidence demonstrates that the ability of effector T cells to traffic to 
the tumor microenvironment correlates best with tumor regression rather than a specific 
quantity of systemically measured T cell responses 
50,96
. In untreated KPC mice, effector 
CD8
+
 T cells fail to infiltrate PanINs and PDA 
51
. I therefore evaluated whether PC61 and 
Cy given with the LM-Kras vaccine sequestered the effector T cell populations from the 
periphery, recruiting them into the pre-malignant pancreas. In support of this hypothesis, 
I observed a significant increase in the number of CD3
+
 T cells within the pancreata of 
mice treated with PC61 and Cy with LM-Kras relative to the LM-Kras alone-treated mice 
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(Figure 9E). This increase in CD3
+












T cells in mice treated with PC61, Cy, and the LM-Kras vaccine was confirmed by 
immunohistochemistry (IHC) (Figure 9F).  
 
Combination immunotherapy alters the cytokine milieu in PanINs  




 T cells into the pancreas, a higher 






 T cells found within PanINs of mice treated 




, indicating an antigen-experienced 
phenotype when compared with the vaccine alone group (Figure 10A). Although 
attempted, the small number of cells in the pancreas limited the use of an ICS assay to 
assess the T cell response to Kras with peptides directly ex vivo.  However, anti-
CD3/CD28 beads were used to stimulate lymphocytes isolated from the pancreata of LM-
Kras treated and LM-Kras plus PC61/Cy-treated mice that began immunotherapy 
treatment at 4-6 weeks of age, allowing for evaluation of the cytokine profile of all 
PanIN-infiltrating T cells. In the mice receiving combination therapy, there were 
significantly more IFN and TNF-producing CD4
+
 T cells and increased numbers of IL-
17-producing CD4
+




 T cells were 
observed in mice receiving the combination of PC61 and Cy with the LM-Kras vaccine 




 T cells, the transcription factors 





 T cells within the pancreas, there was also a trend toward increased IL-17, IFN, 
and TNF-producing CD8
+
 T cells with the combination of LM-Kras and PC61/Cy 






 T cells (Figures 10C 
and E).  
I further investigated the ability of LM-Kras to produce IL-17 responses in the 
tumor microenvironment and the periphery. First, I used a GM-CSF-secreting irradiated 
tumor cell vaccine derived from KPC tumors (GVAX), similar to vaccines which are 
currently in clinical trials for human PDA, to test the ability of other vaccine platforms to 
induce IL-17-secreting cells in mouse PDA. IL-17 production was not unique to LM-





 T cells in PanINs of treated mice, although not to the extent 
of LM-Kras (Figures 11A-B).  Secondly, as the production of IFN by T cells in the 
spleen following LM-Kras had been demonstrated and decreased peripheral numbers of 
these cells in the spleen correlated with enhanced numbers in the tumor 




 splenocytes for the production of 
IL-17 to determine the relationship to IL-17-producing cells in the pancreatic 




 T cells from the spleens of both LM-
Kras alone and LM-Kras plus PC61/Cy-treated mice failed to produce IL-17 above 
background levels present in the untreated mice (Figures 11C-D).  Therefore, the 
peripheral response to LM-Kras does not seem to explain IL-17 production in the tumor 
microenvironment and this response is likely shaped from additional factors relating to 






 T cells and IL-17 are required for delaying PanIN progression  
 To confirm that the delay in PanIN progression to PDA observed in KPC mice 
treated with PC61/Cy and LM-Kras during early PanIN development is CD8
+
 T cell 
dependent, 4-6 week old mice were treated with LM-Kras plus Cy and PC61 and with 
either the CD8-depleting antibody, 2.43 
19
, or a control antibody.  Mice were sacrificed 5 
weeks after completing two LM-Kras and Cy/PC61 treatment cycles (age 9-11 weeks).  
Since these younger treated mice are expected to have lower stage PanINs at this early 
time point and this time point was too early to observe major differences in survival or 
tumor development, we quantified the percent of the total tissue area per slide occupied 
by acinar-ductal metaplasia (ADM), PanIN 1, 2, 3, and PDA using a stereology method 
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rather than giving each pancreas a single grade representing the predominant lesion stage. 
KPC mice receiving PC61/Cy and LM-Kras immunotherapy with the control (rat IgG) 
had a lower percentage of tissue occupied by late stage PanINs (PanIN 2 and 3) when 
compared to mice receiving the same treatment and CD8
+
 T cell depletion, while levels 
of ADM and low grade PanINs (PanIN 1) were similar in both groups (Figures 12A-B).  
CD8-depletion did not have an effect on PanIN stage in unvaccinated mice, consistent 
with the lack of CD8
+
 T cells in the pancreas of untreated mice (Figures 12C-D). While 
it cannot be determined if CD8
+
 T cell-depleted mice would have developed PDA at a 
faster rate given this early time point, the data suggest that effector CD8
+
 T cells induced 
by the combination therapy are at least partially responsible for protection against the 
progression of early to late stage PanINs. As shown in Figures 9 and 10, CD4
+
 T cell 
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infiltration is also enhanced in the pancreas of KPC mice treated with PC61/Cy and LM-
Kras, with increased Th1 and Th17 subsets and a decreased Treg subset, suggesting that 
Th1 and Th17 effectors likely contribute to inhibition of PanIN progression as well. As 
total CD4
+
 T cell depletion may have a mixed effect due to the various CD4
+
 T cell 
subtypes found in pancreata of treated KPC mice and Th1 cells already have a recognized 
role in protecting against cancer, I tested the effect of IL-17 depletion in KPC mice 
treated similarly to mice in the CD8
+
 depletion experiments 
97
. As before, pancreata were 
harvested in the fifth week of treatment and the percent of tissue occupied by each PanIN 
stage was assessed by the stereology method. KPC mice treated with LM-Kras and 
PC61/Cy with ongoing IL-17 depletion had similar amounts of tissue occupied by ADM 
and PanIN 1, but a significantly increased percent of tissue with late stage PanINs (2 and 
3) and PDA when compared to mice treated with PC61/Cy and LM-Kras and a control 
antibody (Figures 12E-G). There were no significant differences in IL-17-depleted or 
control-treated KPC mice that did not receive the LM-Kras vaccine and Treg depletion 
(Figures 12H-I).  Thus, these studies confirm that both CD8
+
 T cells and IL-17 secreting 
effector T cells are each contributing to the slowing of PanIN progression following Treg 
depletion given with the LM-Kras vaccination. 
 
LM-Kras and PC61/Cy enhances the recruitment of pancreatic Gr-1
+
 cells  
MDSC have been shown to infiltrate PanINs and PDA in KPC mice, promoting 
tumorigenesis and inhibiting effector T cells 
51,77
. I also observed an intense infiltration of 
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mixed morphology leukocytes by H&E stain in late stage PanINs and PDA, regardless of 
treatment group. This was an interesting observation given the presence of IL-17-
producing T cells in the pancreata of LM-Kras and PC61/Cy-treated mice, which can 
recruit monocytes, macrophages, and neutrophils 
98
. I evaluated the effect of 
immunotherapy on myeloid cell recruitment more systematically with flow cytometry 
and IHC. First, I investigated the effect of LM-Kras and PC61/Cy individually on the 
systemic myeloid populations. The effect of PC61 and Cy, with or without LM-Kras, was 




 cells, with a trend towards a 




 cells, in the spleen (Figure 13A). With PC61 and Cy 
alone, there was also a statistically significant expansion of F4/80
+
 macrophages 
compared to LM-Kras alone or the combination of LM-Kras and PC61/Cy (Figure 13A). 
In the pancreatic microenvironment, total Gr-1
+ 









 populations, were of similar or increased total number as well as by 
percentage of total CD11b
+
 cells in LM-Kras plus PC61/Cy-treated mice when compared 
to LM-Kras alone or untreated mice of the same age (Figures 13B-D). There was no 
statistically significant difference in the number or percent of F4/80
+
 macrophages in 
LM-Kras plus PC61/Cy-treated mice compared to vaccine alone or untreated mice 




 cells were the predominant Gr-1
+
 population identified 
with flow cytometry so the Ly6G marker was chosen for IHC. Ly6G
+
 cells began 
infiltrating in mid-stage PanINs and increased with progression to PDA in untreated KPC 
mice (Figures 13F-H). In comparison to similarly staged untreated mice, both LM-Kras 
alone and LM-Kras plus PC61/Cy-treated mice also had abundant infiltration of Ly6G
+
 
cells (Figures 13I-K). F4/80
+
 macrophages were less numerous, but nevertheless also 
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showed a similar increased infiltration with progression from early stage PanIN to PDA 
in untreated KPC mice (Figures 13L-N) and were similar in abundance between treated 
and untreated mice (Figures 13O-Q).  
 
LM-Kras and Treg depletion repolarize PanIN-infiltrating Gr-1
+
 cells  
             As the number of Gr-1
+
 myeloid cells and F4/80
+
 macrophages was either 
increased or unchanged with LM-Kras and PC61/Cy treatment compared to untreated 
KPC mice, I hypothesized rather than inhibiting innate immune cells from infiltrating the 





 cells have previously been shown to be suppressive in the KPC mouse 
model of PDA, Ly6C and Ly6G are expressed by both the immature and mature 
counterparts of cells in the myeloid and granulocytic lineages and potentially represent 
less suppressive cell populations in our treatment model 
99
. As with T cells, innate 
immune cells can be either pro-tumorigenic (M2/N2-polarized macrophages and 
neutrophils) or anti-cancer (M1/N1-polarized macrophages and neutrophils) depending 
on the microenvironment cytokine milieu 
4







 cells from the pancreata of mice treated with two cycles of LM-
Kras, LM-Kras with Cy/PC61, or left untreated, and found that LM-Kras with or without 
Treg depletion was able to induce IL-12 secretion in Gr-1
+
 cells, which resulted in an 
increased total number of IL-12-secreting Gr-1
+
 cells in LM-Kras and PC61/Cy-treated 
pancreata (Figure 14A). While PanIN-infiltrating macrophages also produced IL-12, 
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there were no statistically significant differences between groups, except for in the 
percentage of IL-12-producing cells between LM-Kras alone and untreated mice (Figure 
14B), demonstrating that while macrophages may also be repolarized by LM-Kras, the 
predominant shifts between treatment groups occur in Gr-1
+
 population.  There was no 
significant difference in IL-10 production by F4/80
+
 macrophages or Gr-1
+
 cells by 




 cells from the pancreata of 
treated mice also secreted higher levels of many other immunostimulatory cytokines than 
untreated mice (Figure 14C).  PC61/Cy and LM-Kras-treated Gr-1
+
 cells were capable of 
producing more cytokines than LM-Kras alone-treated Gr-1
+
 cells although either 
treatment resulted in upregulation of these pro-inflammatory cytokines compared to 
untreated Gr-1
+
 cells. These included chemokines responsible for recruiting myeloid and 
lymphoid cells such as CCL-1, CCL-2 (MCP-1), CCL-3 (MIP-1), CCL-4 (MIP-1), 
CCL-5 (RANTES),  CCL-11 (Eotaxin), CCL-12 (MCP-5), CXCL-2 (MIP-2), CXCL-9 
(MIG), CXCL-10 (IP-10), CXCL-12 (SDF-1), M-CSF, and IL-16, and the N1-associated 
cytokines TNF, IL-12, IFN, IL-6 , and IL-7. There was an upregulation of cytokines 
responsible for promoting Th(c)1 and Th(c)17 responses (IL-23, IL-12, IFN, and  IL-
27), and a downregulation of IL-4, responsible for promoting Th2 responses. Due to 
limited number of cells from each mouse and the large amount of cell lysate needed for 




 sorted cells in 
one treatment group and thus, the resulting data is more qualitative, rather than 
quantitative, in nature but serves to demonstrate that Gr-1
+
 cells from treated pancreata 







 cells sorted from the pancreata of KPC mice treated with 
LM-Kras with or without Treg depletion or left untreated, I analyzed suppressive 
capability on naïve isogenetic CD8
+
 T cells stimulated with anti-CD3/CD28 beads for 3 
days. Due to the small numbers of cells available for the suppression assay which limited 
the number of replicates for any given experiment, this experiment was repeated several 




 cells isolated 
from untreated KPC pancreata suppressed T cell proliferation while LM-Kras and 
Cy/PC61-treated Gr-1
+
 cells caused levels of cell division in naïve CD8
+
 T cells which 
were closest to CD8
+
 T cells stimulated in the absence of Gr-1
+
 cells, as shown in one 
representative experiment (Figure 14D).  LM-Kras and PC61/Cy treatment induced Gr-
1
+
 cells which allowed for significantly higher T cell proliferation than Gr-1
+
 cells from 
untreated pancreata in two of the three experiments and showed the same trend in a third 
(Figure 14E). LM-Kras alone-treated Gr-1
+
 cells cultured with CD8
+
 T cells resulted in 
an intermediate amount of cell division compared to the effects of LM-Kras and 
Cy/PC61-treated and untreated Gr-1
+
 cells, in one representative experiment (Figure 
14D). Repeated experiments revealed significantly enhanced proliferation of T cells 
when cultured with LM-Kras-treated Gr-1
+
 cells compared to untreated Gr-1
+
 cells 






 cells fail to drive cytokine production of T cells 
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 cells from LM-Kras and PC61/Cy-
treated KPC pancreata were less suppressive to CD8
+
 T cell proliferation and secreted 
many cytokines which could be responsible for recruiting and shaping the T cell 
response, I evaluated the ability of Gr-1
+
 cells to drive cytokine production in both naïve 





cells in T cell production of IFN and IL-17 in mice treated with LM-Kras and PC61/Cy, 
Ly6G
+
 cells were depleted with an anti-Ly6G monoclonal antibody throughout the course 




 are the main Gr-1
+
 cell population in the pancreata of 
KPC mice. In verifying that Ly6G
+ 
cells were depleted, one caveat of this study was 




 cells expanded in the spleen and pancreata of mice 
treated with the antibody to Ly6G (Figures 15A-B). There was no effect on F4/80
+ 
cells 
in the spleen or pancreas (Figures 15A-B). Without Ly6G
+
 cells in the pancreas 





 T cells by the percentage of cells expressing IL-17 or IFN nor by the 
total number of cytokine-producing cells per mg of pancreas compared to isotype control-




 cells are not 
responsible for driving IFN or IL-17 production in pancreatic lymphocytes, it is also 





cells can contribute to T cell phenotype in the absence of Ly6G
+
 cells.  
 Thus, to more directly evaluate the effect of the pancreatic Gr-1
+
 cells on shaping 




 cells from the pancreata of KPC mice 
left untreated or treated with LM-Kras alone or in combination with Treg depletion and 
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 T cells in the presence of anti-
CD3/CD28 beads or for the IL-17 ICS assay, anti-CD3/CD28 beads, IL-6, TGF, anti-
IFN and anti-IL-4 as naïve T cells are unlikely to develop to a IL-17-producing 
phenotype without additional signals. Gr-1
+ 
cells from PC61/Cy and LM-Kras-treated 




 T cells 
compared to Gr-1
+
 cells derived from untreated KPC pancreata (Figure 15E).  The only 
observed change in cytokine production was that co-culture with Gr-1
+
 cells from any 
treatment group decreased the percentage of T cells that could produce cytokines in 
comparison to the stimulated T cells alone, although this could have been a non-specific 
effect and the percentage of cells producing cytokine did not reach the low level observed 





 cells to drive either Th(c)1 and Th(c)17 phenotypes although it is possible 
that they contribute to the maintenance of these in the tumor microenvironment along 
with other cell populations and signals present in mice treated with immunotherapy. It is 
also possible that their recruitment and phenotype is induced by activated T cells versus 
inducing or maintaining activated T cells themselves. 
 
Increased RORt-expressing human lymphocytes following Listeria administration 
 Listeria vaccines are being actively evaluated in several clinical trials in settings 
of advanced cancer using the same attenuated vector utilized here to target mutated Kras.  
We therefore evaluated lymphocyte subsets from patient tumors following Listeria 
75 
 
administration to determine whether IL-17 is a mediator of LM vaccine response in 
patients 
82
. We obtained tissue from a patient with malignant pleural mesothelioma who 
received CRS-207, a recombinant Listeria vaccine expressing mesothelin 
82
, prior to 
vaccination and following 2 prime vaccination doses given 2 weeks apart. Staining for 
RORt revealed enhanced staining at the post-LM time point (Figure 16A). Staining of 
serial sections from each time point with anti-CD3 revealed that the intranuclear RORt 
staining correlated with CD3
+
 cells in the post-LM biopsy (Figure 16B). CD3
+
 cells in 





















 In this chapter, I report several new findings relevant to the treatment of 
pancreatic cancer and premalignant lesions with immunotherapy.  First, a Listeria 
monocytogenes vector targeting the earliest driver gene in pancreatic cancer initiation, 
mutated Kras, can prolong PanIN progression to PDA and increase survival in young 
mice with the earliest stages of PanINs only when Tregs are simultaneously reduced 
within the pancreata. Second, vaccination with LM-Kras is able to induce Kras-specific T 
cell responses that are necessary but not sufficient to delay PanIN progression in Kras-
expressing mice that are genetically programmed to develop the multiple stages of pre-
malignant PanINs prior to developing PDA. Third, prolonged survival as a result of 
vaccination with the LM-Kras vaccine given in sequence with Treg depleting therapy is 
associated with enhanced T cell trafficking into the pancreas and an alteration in cytokine 
profiles toward increased IFN, TNF, and IL-17. Fourth, Treg depletion together with 
an LM-Kras vaccine shifts the immunosuppressive phenotype of innate immune cells 
present in PanINs towards a more immunostimulatory anti-tumor population. 
This is the first example of a vaccine targeting the initiating driver gene for a non-
virus induced cancer that can prevent pre-malignant lesion progression. Specifically, a 
LM vaccine targeting the earliest mutated gene, Kras, that is involved in PDA 
development, is effective in prolonging survival in KPC mice.  This vaccine is only 
effective when given early at the time of the earliest genetic alteration and even at this 
earliest stage requires Treg depletion within the pancreata.  This result is consistent with 
our finding that Tregs are present in early PanIN lesions and increase in abundance with 
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PanIN progression and invasive tumor development. These data support the testing of 
vaccine based therapy in patients who are at high risk for developing cancer and also 
highlights the importance of initiating cancer immunotherapy at an early stage of disease 
development. The fact that the LM-Kras vaccine worked best at preventing progression 
of the earliest PanIN lesions and did not have an effect on mice harboring more advanced 
pre-malignant PanINs was not surprising since pre-clinical models demonstrate that 
vaccines can work well in cancer bearing mice, but only when paired with modulation of 
the pre-existing systemic and local tolerance to tumor antigens 
49,71,78
. Our findings are 
consistent with data from studies testing two human vaccines that are approved for 
preventing virus-associated cancers, HPV-associated cervical cancer and HBV-associated 
hepatomas. Even though these vaccines target virally associated proteins that should be 
perceived as foreign by the immune system, both vaccines work best when given to 
young individuals who have not yet been exposed to the virus and its proteins 
100,101
. 
Taken together, these observations would suggest that mechanisms of immune 
suppression within the target organ of cancer development occur very early, at the time of 
the earliest genetic alteration and the development of the earliest pre-malignant lesion.  
Thus, future studies should evaluate immune-suppressing mechanisms within target 
organs in which pre-malignant lesions develop to identify the multiple mechanisms 
involved in early immune suppression.  
Cancer progressed when KPC mice were treated with the LM-Kras vaccine alone 
even though the vaccine induced a significant peripheral CD8
+
 T cell response directed 
against an epitope within the Kras protein containing the oncogenic mutation, 
78 
 
demonstrating that the induction of T cells by a LM vaccine targeting a mutation does not 
constitute effective anti-tumor immunity or true breaching of “self-tolerance.”  This data 
is consistent with previous findings that elevated levels of systemic T cell responses to a 
viral HPV antigen encoded by LM vaccines do not correlate with efficacy in an 
orthotopic model of cervical cancer 
102
 despite a well documented requirement for CD8
+
 
T cells for efficacy of the vaccine 
89
. Furthermore, systemic CD8
+
 T cell responses to 
tumor antigens are insufficient for preventing disease progression in patients with PDA 
and malignant melanoma 
74,103
.  These data also have implications for developing vaccine 
approaches that target multiple mutations within a sequenced tumor, an approach that is 
being developed as part of individualized vaccine therapy for cancer treatment 
104,105
.  
Specifically, targeting mutated proteins, even recently developed mutations, may not be 





 have been shown to reduce Treg numbers and 
function within developing tumors and their draining lymph nodes, improving effector T 
cell number and function within the nodes and facilitating trafficking into tumors 
50,106
.  
However, this has been shown mainly in transplantable tumors derived from cancer cell 
lines and grown subcutaneously in mouse models. The KPC mouse model mimics 
naturally developing human PDA, a tumor characterized by hypovascularity and 
surrounded by a dense fibrotic stromal response 
53,107
. Unlike transplantable PDA, 
spontaneously developing pancreatic tumors in mice are resistant to gemcitibine unless 
the stromal desmoplastic reaction is inhibited 
54,108
. PanINs and PDA in this mouse model 
may also differ in susceptibility to penetration by other chemotherapeutic agents, 
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including Cy, explaining the statistically significant depletion of Tregs in the draining 
lymph nodes but not the tumor.
 
Regardless, Cy and PC61 had an effect on the number of 
Tregs found in the tumor draining lymph node, an important site for orchestrating tumor 
antigen tolerance 
14,75




 effector T 
cell numbers in the pancreas.  
Cy has also been shown to have additional effects on the cytokine milieu in the 
tumor microenvironment, promoting the development of both IL-17 and IFN-secreting T 
cells 
109,110
. In our study, there was a shift towards increased numbers of Th1 and Th17 
cells in mice treated with the LM-Kras vaccine given with PC61 and Cy as compared to 
mice treated with the LM-Kras alone, and depletion of IL-17 throughout treatment with 
combination immunotherapy abrogated the combination treatment’s effect on slowing of 
PanIN progression to PDA. Recent evidence has shown that in addition to traditional Th1 
effector cells, Th17 cells also have potent anti-tumor effects. In a transplantable 
melanoma model, adoptively transferred Th17 CD4
+
 T cells were superior to Th1 CD4
+
 
T cells as measured by dendritic cell and CD8
+
 T cell recruitment and tumor eradication, 
which may be due in part to the ability of Th17 cells to persist and develop into other Th 




Increasing evidence supports the concept of plasticity among the 
different CD4
+
 T cell subsets and the existence of pathogenic and non-pathogenic 
populations even with the same defined Th subset 
4,113
. Tc1 and Tc17 cells have both 
been shown to be effective in mouse tumor models through different mechanisms; Tc1 
directly through the expression of tumor-cytotoxic IFN, and Tc17 through the capability 





Additionally, the production of IFN and cytotoxic effects of Tc17 cells can be 
potentiated by IL-12, a cytokine produced in response to natural Listeria infection and the 
LM vaccine used in our study, and a cytokine I also observed produced in response to 
LM by innate cells in the pancreas 
91,116
. Although IL-17 has also been implicated in the 
recruitment of neutrophils and MDSC which can promote cancer progression, IL-17 can 
also recruit tumor-associated neutrophils which promote anti-cancer responses, 
depending on the context and tumor type 
117,118
. It is possible that our observation of 
Th1/Th17 and Tc1/Tc17 phenotypes represents a period during which T cell subsets are 
undergoing reprogramming in response to the change in the microenvironment, in this 
case due to treatment with the LM-Kras vaccine and removal of Tregs.  If true, this would 
provide a window of opportunity for re-directing a potentially pro-oncogenic or 
inhibitory inflammatory response in the cancer susceptible organ microenvironment, to 
an effective anti-tumor immune response.   
Cells of both neutrophil and macrophage lineages accumulate with increasing 
frequency with PanIN progression, underscoring the concept that inflammation caused by 
acute and chronic pancreatitis is associated with pancreatic cancer development 
119,120
. 
Cytokines such as IL-8 and GM-CSF, which can recruit innate inflammatory cells, are 




Additional inflammatory mediators play a role in PDA progression, including NF-B, 
STAT3 and matrix metalloproteinases 
122-124
. Constitutive activation of these pathways 
leads not only to inhibition of apoptosis in pre-neoplastic and PDA cells, but also, to 
innate inflammatory cell recruitment and signaling 
122-124
. Subsequent fibrotic remodeling 
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of the stroma and release of pro-inflammatory cytokines and proliferative factors 
promotes further genetic alterations and suppresses protective immune responses 
107,125
. 
Surprisingly, I found that LM-Kras given with PC61 and Cy in early stage PanINs, 













 cells. However, I also found that the 
addition of LM-Kras, with or without Treg depletion, resulted in a higher percentage of 
IL-12-producing Gr-1
+
 cells in the tumor microenvironment and numbers of these IL-12-
producing cells were the greatest with LM-Kras and Cy/PC61. One potential explanation 
for this change in phenotype is pro-inflammatory cytokines secreted after infection of 
APCs by LM, including IL-12 
91
.  IL-12 with Cy co-administration has been shown to 
alter the phenotype of cells infiltrating tumors from MDSC to less suppressive immature 
myeloid cells 
126
.  Additional cytokines and chemokines secreted by the less suppressive 
Gr-1
+
 population in LM-Kras and PC61/Cy-treated mice may actually enhance the 
protective T cell response, which is further supported by the ability of Gr-1
+
 cells from 
treated mice to stimulate, rather than suppress, T cell proliferation. To this end, I tested 
the direct effect of Gr-1
+
 cells from the pancreata of treated or untreated mice on naïve T 
cells to drive cytokine production and found that the effects of Gr-1
+
 cells from LM-
Kras-treated and Treg depleted KPC mice were minimal. Despite differences in 
suppressive capability and production of immunostimulatory cytokines, Gr-1
+
 cells did 




 T cells; however, it is possible 
that they play a role in maintenance of T cell activation and phenotype in the tumor 
microenvironment. At the very least, the lack of suppression from MDSC (which has 
previously been shown in this model of pancreatic cancer) likely contributes to a more 
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productive and protective T cell response 
77
.  Further studies are required to investigate 
additional alterations in inflammatory signals and cell populations in the developing 
pancreatic tumors and the role of vaccination and Treg depletion in these tumor 
microenvironment changes. Polarization of these cells towards an anti-tumor phenotype 
should serve as a therapeutic goal in the treatment of PDA, both in the early and late 
stages. 
 Listeria vaccines represent an effective strategy for inducing immune responses to 
tumor antigens. In our study, the altered LM vector was transformed with a construct 
encoding a segment of the Kras gene containing the G12D mutation, a common mutation 
in human PDA and the same mutation found in the KPC transgenic mouse model 
80,88
. 
However, this vector is easily modified to express other cancer-associated proteins, can 
express multiple antigens within the same vector, and has shown safety and the induction 
of immune responses in patients with PDA 
82
.  Furthermore, LM vaccination was 
associated with enhanced RORt expression in a Listeria-treated patient with malignant 
mesothelioma. While these studies will need to be expanded as clinical trials utilizing LM 
vaccines in cancer patients progress, this suggests LM vaccines may be particularly 
efficacious in inducing potent anti-cancer phenotypes in tumor-infiltrating lymphocytes.  
 Despite effective induction of immune responses with LM-Kras vaccination, this 
was not sufficient to protect against PDA and delay progression of PanINs unless 
intervention included Treg-depleting therapies and was initiated at an age representative 
of the earliest PanIN stages. Early intervention with the combination of LM-Kras 




 T cells at the site 
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of tumor development and decreased the suppressive phenotype in myeloid cells found 
infiltrating PanINs. Future vaccine strategies require incorporating agents designed to 
alter the inflammatory milieu within the developing tumor’s microenvironment, even 
when designed for prophylactic treatment of patients with premalignant lesions or with a 




Figure 7. Immunogenicity of the LM-Kras vaccine. (A) Synthetic 12ras construct.  
Activated ras 25mers cloned downstream of the actA promoter are connected with a 
linker and tagged with immunologic positive control T cell epitopes for Balb/c mice 
(“A”, SYIPSAEKI) and C57BL/6 mice (“B”, SIINFEKL) as well as a C-terminal 
antibody epitope (“C”, Myc). (B) Sequence of epitopes used to test immunogenicity of 
the LM-Kras vaccine, with mutant residue 12 in bold. (C) 129/SvJae/C57Bl/6 mice (n = 
5) were injected with LM-Kras via tail vein and 7 days later splenic CD8
+
 T cell 
responses were assessed after incubation with the indicated peptide and T2K
b
 cells by 
intracellular staining for IFN. Significantly increased levels of IFN-producing CD8
+
 T 
cells were noted for Kras B, Kras C, Kras D, Kras E, Kras F, and Kras G. (D) 6-9 week 
old KC mice were vaccinated with the LM-Kras vaccine or left untreated. At 7 or 14 days 
post-vaccine animals, IFN secretion by CD8
+
 T cells isolated from the spleen was 
assessed as in (C). (E) 4-6 week old Kras
G12D/+
; Pdx-1-Cre  (n = 5) and Kras
G12D/+
; 
Trp53R172H;Pdx-1-Cre  (n = 7) mice were treated with LM-Kras twice four weeks apart, 
sacrificed one week post-vaccine, splenocytes were harvested, and intracellular cytokine 
staining was used to assess response to KrasF and Trp2 peptides as in (C-D). No 
significant difference in IFN production was found in the response to KrasF. (F) 
Cumulative results of 5 experiments showing no significant difference in the magnitude 
of CD8
+
 T cell responses to Kras F in mice expressing the Kras
G12D
 mutation compared 
with littermates not expressing the mutation (KrasG12D
-








Figure 8. Effect of vaccination and Treg depletion on KPC mice. (A) Several Foxp3
+
 
cells can be seen per 40x field in the pancreas of KPC mice containing an early stage 
PanIN (left, PanIN 1), mid-stage PanIN (middle, PanIN 2) and PDA (right). (B-C) 
Splenocytes were harvested from 4-6 week old KPC mice one week after vaccination 
with LM-Kras. PC61 and Cy was given one day prior to vaccine, according to treatment 





representative LM-Kras-treated KPC mouse versus LM-Kras and PC61/Cy-treated KPC 
mouse.  (C) The percentage of Foxp3
+
 cells in CD4
+
-gated splenocytes from LM-Kras 
and PC61/Cy-treated KPC mice is significantly decreased in comparison to LM-Kras-
treated KPC mice (n = 4 per group, ***P<0.001). (D) KPC mice (n = 11-30 per group) 
less than 2 months old were injected with LM-Kras with or without pretreatment 24 hours 
prior with PC61 and Cy or with Treg depletion alone. Booster vaccinations were 
administered monthly with or without pretreatment according to group assignment and 
animals were monitored for survival. Log rank (Mantel-Cox) analysis showed a 
significant improvement in survival in the combination group relative to no treatment (p 
= 0.002) and to Treg depletion or LM-Kras vaccine alone (p = 0.048 and p = 0.050, 
respectively). There was no statistically significant difference in survival between the 
untreated group and animals receiving PC61/Cy without LM-Kras or between untreated 
and LM-Kras. (E) Mice older than 2 months were treated and monitored as in (D). No 
statistically significant difference was noted in survival between groups using Mantel-
Cox analysis. (F) Young (4-6 week old) and older (8-12 week old) KPC mice were 
vaccinated with LM-Kras and splenocytes were harvested one week later, stimulated with 
KrasF and Trp2 peptides, and ICS used to assess response. The CD8
+
 T cell response to 
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KrasF is normalized for control peptide (Trp2) response. Total numbers of CD8
+
 T cells 
responding to KrasF were calculated based on percent responders and total number of 
CD8
+
 T cells per spleen (n = 5-6 per group). (G) 4-6 week old KPC mice (n = 4-6 per 
group) were treated with either LM-Kras, PC61/Cy, the combination, or left untreated. 
Treatment was repeated at 4 weeks based on group assignment and at week 5, animals 






Figure 9. Systemic and local T cell responses with Treg depletion and LM-Kras. 4-6 
week old KPC mice were harvested after 2 cycles of treatment with LM-Kras with or 
without Treg depletion, 1 week after the second vaccine. (A) The percentage of splenic 
CD8
+
 cells producing IFN in response to KrasF and Ova peptides were normalized for 
response to negative control peptide (Trp2) and total numbers were calculated from the 
normalized percentages and the total number of CD8
+
 T cells per spleen. (N.S. = not 
significant, n = 6-9 per treatment group). (B) Splenocytes were stimulated with anti-
CD3/CD28 beads overnight, followed by 5 hour incubation with Golgi-Stop and 
intracellular cytokine staining. IFN was gated on non-stimulated controls (N.S. = not 


















 cells in the pancreas, but this was not significant (n = 
5-10 per treatment group). (D) Mice treated with the LM-Kras vaccine without Treg 
depletion have many Foxp3
+
 T cells per 40X field (left panel), whereas mice treated with 
PC61/Cy and the LM-Kras vaccine have few Foxp3
+
 T cells within the pancreas (right 








 cells per mg of pancreas is 
shown for mice treated with PC61/Cy and LM-Kras or vaccine alone (n = 7-8 per group).  
(F) Immunohistochemistry of mice left untreated (right), treated with LM-Kras (middle) 
or LM-Kras and PC61/Cy (left) for CD4 (top) and CD8 (bottom) at 20X magnification. 
All data are representative of two or more independent experiments. Populations of cells 
positive for cell surface markers and cytokines were gated using isotype controls and 








Figure 10. Phenotypic shifts in pancreatic lymphocytes with LM-Kras and Treg 
depletion. LM-Kras with or without PC61/Cy pre-treatment was given to mice aged 4-6 
weeks old mice at week 0 and week 4, and pancreata were harvested at week 5. (A) 







and analyzed for CD62L and CD44 expression. PC61/Cy 







 (top panel) or CD8
+
 cells (bottom panel). (B-E) Pancreatic 







(n = 4 samples of 3 pooled pancreata per group). LM-Kras and 








 T cells (B) and 















 (D) and CD8
+
 (E) cells are shown for PC61/Cy and LM-
Kras and LM-Kras alone-treated mice. Data are representative of two or more 
independent experiments. Populations of cells positive for cell surface markers and 










Figure 11. IL-17 production by PanIN-infiltrating T cells induced by LM-Kras or 
GM-CSF-secreting vaccines and the peripheral IL-17 T cell response. (A-B) 4-6 
week old KPC mice were treated with LM-Kras and PC61/Cy as in previous experiments 
or PC61/Cy followed one day later by GM-CSF-secreting irradiated KPC tumor cell 
vaccine (GVAX). Treatment was repeated 4 weeks later and pancreata harvested one 
week post vaccination. Lymphocytes were stimulated overnight with anti-CD3/CD28 
beads. The percentage of CD4
+





T cells per mg of pancreas for LM-Kras and GVAX-treated mice is shown in (A) and the 
percentage of CD8
+




 T cells per mg of 
pancreas in (B) (n = 3 samples, 2-3 pancreata pooled per sample). (C-D) 4-6 week old 
KPC mice were treated with LM-Kras, LM-Kras and PC61/Cy, or left untreated for two 
cycles of treatment. Spleens were harvested 1 week post vaccine and splenocytes were 
stimulated overnight with anti-CD3/CD28 beads as in previous experiments. Percentage 
of T cells producing IL-17 and the total number of cells per spleen is shown for CD4
+
 T 
cells in (C) and for CD8
+
 T cells in (D) (n = 1-3 mice per group).  
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Figure 12. PanIN progression with the depletion of CD8
+
 cells or IL-17. (A-I) Mice 
were treated with LM-Kras and PC61/Cy or left untreated for two cycles of therapy 
together with depleting antibodies for CD8 (A-D) or IL-17 (E-I) or with isotype control 
prior to and throughout the course of treatment. Following harvest, two slides per 
pancreas were assessed for percent of tissue occupied by each PanIN stage, acinar-ductal 
metaplasia (ADM), and PDA. Percentage of tissue occupied by each lesion (A) or by 
PanIN 2 and 3 together (B) in KPC mice treated with LM-Kras and PC61/Cy and anti-
CD8 or isotype control (n = 12 per group). Percentage of tissue occupied by each lesion 
(C) or by PanIN 2 and 3 together (D) in KPC mice left untreated and CD8-depleted or 
given isotype control (n = 6-8 per group). Percentage of tissue occupied by each lesion 
(E), by PanIN 2 and 3 together (F), or by PDA (G) in KPC mice treated with LM-Kras 
and PC61/Cy while given IL-17 neutralizing antibody or isotype control (n = 15-16 per 
group). In (H) and (I), the percent tissue occupied by each lesion and by high grade 
PanINs (PanIN 2 and 3) is shown for IL-17-depleted and isotype control-treated KPC 









Figure 13. Myeloid cell recruitment into untreated and treated spleens, PanIN, and 
PDA. (A) Spleens of KPC mice treated with PC61/Cy, LM-Kras, or the combination 
were harvested one week post-vaccination after 2 cycles of therapy beginning at 4-6 
weeks old and analyzed for the percents of the various cell populations (n = 2-3 per 
group). (B-E) Pancreata from KPC mice treated with two cycles of LM-Kras with or 
without PC61/Cy starting at 4-6 weeks old or left untreated for the same timeframe were 
analyzed by flow cytometry (n = 4-6 mice per group). The percentage of Gr-1
+
 cells of 
CD11b
+




 cells of CD11b
+





 cells of CD11b
+




 cells (E)  and 
the total numbers of each per mg of pancreas (B-E) is shown for all 3 treatment groups. 
Representative of two experiments. (F-Q) Pancreata were harvested from KPC mice of 
various ages, representing early and late PanIN stages and PDA, or from 4-6 week old 
KPC mice treated with two cycles of LM-Kras with or without Treg depletion, and slides 
were stained with Ly6G or F4/80 antibodies. Representative images of Ly6G staining are 
shown for the following: untreated PanIN 1 (F), untreated PanIN 2/3 (G), untreated PDA 
(H), LM-Kras-treated PanIN 1 (I), PC61/Cy and LM-Kras-treated PanIN 1 (J) and 
PC61/Cy and LM-Kras-treated PanIN 1/2 (K). Representative F4/80 staining in: 
untreated PanIN 1 (L), untreated PanIN 2 (M), untreated  PDA (N), LM-Kras-treated 
PanIN 1 (O), PC61/Cy and LM-Kras-treated PanIN 1 (P), and PC61/Cy and LM-Kras-








Figure 14. Phenotype of innate populations in the pre-malignant pancreas of KPC 







 cells from mice treated at age 4-6 weeks 
old with LM-Kras with or without Treg depletion or left untreated for five weeks. Flow 
cytometry plots for a representative sample of each treatment group are shown with 
percentages of the cells found in each quadrant for Gr-1
+
 (top panel) and F4/80
+
 (bottom 




 cells expressing IL-12 or IL-10 




 cells per mg of pancreas is 
shown in (B) (n = 4-6 mice per group). Representative of two experiments. (C) 





from pancreata of untreated, LM-Kras-treated or PC61/Cy and LM-Kras-treated KPC 
mice (n = 10 mice per treatment group, 2 technical replicates each). The fold change in 
expression for Gr-1
+
 cells from the pancreata of treated mice compared to untreated mice 
is shown for each cytokine. (D) Representative flow cytometry plots showing CFSE 
dilution demonstrate enhanced CD8
+
 T cell division with Gr-1
+
 cells pooled from the 
pancreata of LM-Kras and PC61/Cy-treated mice (right) compared to Gr-1
+
 cells from 





 T cells and anti-CD3/CD28 beads, black dashed line: unstimulated 
CD8
+ 
T cells, grey shaded line: CD8
+ 
T cells cultured with anti-CD3/CD28 beads. (E) 
Average percent of cells that have divided as determined by CFSE fluorescence are 
shown from three representative experiments from the following treatment groups: T 
cells cultured with Gr-1
+
 cells from untreated mice (No treatment), LM-Kras-treated mice 
(LM-Kras-treated), or PC61/Cy and LM-Kras-treated mice (PC61/Cy, LM-Kras-treated) 
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(n = 1-3 wells per treatment group per experiment). In addition, mean fluorescence 
intensity for CFSE is shown from one representative experiment for the same treatment 












 cells on the cytokine profile of T cells. (A-D) 
Ly6G-depleting antibody or isotype control was given throughout treatment with LM-
Kras and PC61/Cy to 4-6 week old KPC mice for 2 cycles of treatment. In (A), spleens 
were harvested 1 week after the second vaccine and assayed for the total number of each 
cell population (n = 14 per group). In (B), pancreata were harvested 1 week after the 
second vaccine and assayed for the total number of each cell population per mg of 
pancreas (n = 1-2 mice per group). In (C-D), pancreata were harvested and T cells were 
stimulated overnight with anti-CD3/CD28 beads, followed by intracellular cytokine 
staining. The percentage of CD4
+
 (C) and CD8
+
 (D) T cells expressing each cytokine as 
well as the total number of cells is shown (n = 5 samples per group of 2-3 pooled 





were sorted from the pancreata of 4-6 week old KPC mice treated with 2 cycles of LM-





T cells in the presence of anti-CD3/CD28 beads. The percentage of T cells expressing 
each cytokine is shown (n = 1-2 wells/treatment group representing Gr-1
+
 cells pooled 







Figure 16. Immune infiltrates in pre- and post-vaccination mesothelioma biopsies 
with a Listeria vaccine targeting mesothelin. Serial sections from biopsies of malignant 
pleural mesothelioma in a patient receiving a Listeria vaccine targeting mesothelin (CRS-
207) prior to administration (left panels) and 2 weeks after the second dose (given 2 
weeks following the first dose) of CRS-207 (right panels) were stained with antibodies to 
RORt (A) or CD3 (B). Arrowheads designate cells or areas with cells containing 





Chapter 4: SUMMARY 
 
The widespread use of vaccines to protect against infectious disease has been one 
of the most important developments in human health in the past century and has 
eradicated many pathogens which were once a leading cause of death and illness in the 
United States and worldwide. In recent years, partly due to vaccine-induced protection 
among many other public health interventions, cancer has bypassed infectious disease as 
a cause of mortality in developed countries. Cancer vaccines have the potential to make 
an impact on human health just as traditional vaccines have for infectious disease, albeit 
through different strategies.  As discussed in Chapter 3, vaccines targeting viruses that 
cause cancer such as hepatitis B and human papillomavirus have already seen success in 
decreasing virally-associated cancers in young individuals who have not yet been 
exposed to the pathogens.  However, these types of vaccines often rely on neutralizing 
antibody responses which are ineffective after the virus has infected host cells. Vaccines 
given after there is already established infection have been less effective due to 
mechanisms that pathogens have evolved to evade the immune system. 
 For the majority of cancer types that are not associated with infectious causes, 
immune evasion and tolerance are also barriers to the effective use of cancer vaccines. As 
has been described in this dissertation and outlined in chapter 1, even in early stage 
disease, many immune-suppressing populations have already entered the site of tumor 
development and inhibit protective responses induced by vaccines. To study the 
mechanisms of immune tolerance, I have used two mouse models to mimic human 
disease:  one of pancreatic ductal adenocarcinoma (PDA) and one of mammary 
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adenocarcinoma as well as novel CD8
+
 TCR transgenic and LAG-3
-/-
 mice to better 
understand tumor antigen–specific T cell activation and regulation. In Chapter 2, the 
inhibition of an immune checkpoint, LAG-3, on high and low avidity T cells was tested 
in combination with a whole cell, GM-CSF-secreting, tumor vaccine and Treg depletion 
in the form of low dose Cy. Inhibition of LAG-3 in high avidity CD8
+
 T cells boosted the 
effects of low dose Cy and vaccine to enhance T cell trafficking, activation, and control 
of tumors, but failed to enhance the function of low avidity T cells which already have 
very low levels of cytokine production and ability to traffic to and lyse tumors. Thus, it 
was shown that immune checkpoint blockade is one solution to overcoming suppressive 
tumor microenvironments, but only is useful when a high avidity T cell population exists 
in large numbers and is supplemented with a vaccine and Treg depletion.  
In Chapter 3, I used a mouse model of PDA which is more relevant to human 
disease as it starts with early PDA precursors (PanINs) that progress in a step-wise 
process to metastatic pancreatic cancer, and occurs in the natural organ and site of tumor 
development, acquiring similar features of the tumor microenvironment that have been 
observed in human PDA. Tregs and MDSC are two immunosuppressive populations 
shown to infiltrate early stage PanINs. An anti-CD25 antibody and low dose Cy were 
used to deplete Tregs and the combination of these Treg-depleting agents with a highly 
immunogenic Listeria vaccine targeting Kras was able to switch tumor-infiltrating 
MDSCs to a phenotype more consistent with N1 neutrophils. However, the two Treg-
depleting agents were not enough to completely eliminate Tregs in the pancreas, 
providing evidence of how the dense stroma induced by tumor cells in pancreatic cancer 
is an additional barrier to effective immunotherapy. 
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The role of different immune cell types, both innate and adaptive, in cancer 
immunotherapy was explored in this work. T cells have long been thought of the main 
effector cell type in both cancer and infectious disease. Therefore, in Chapter 2, I studied 
the effect of further enabling potent, high avidity CD8
+
 T cells by inhibiting an immune 
checkpoint. The CD8
+
 intrinsic effects were obviously beneficial in a mouse model of 
breast cancer; however, the effect of deletion of LAG-3 globally and in the tumor 
microenvironment was not as concrete and likely was due to LAG-3 inhibition in 
antigen-presenting cells and other innate immune cell types. These mixed results on 
CD8
+ 
T cells when LAG-3 signaling was abrogated in all cells have ramifications for the 
use of LAG-3 blocking antibodies in the treatment of cancer patients.  In Chapter 3, the 
interaction of T cells with other cells in the tumor microenvironment was again studied. 
A Listeria vaccine was able to induce Kras-specific CD8
+
 T cells and when given with 
Treg depletion, allowed for trafficking into the pre-malignant pancreas. Increases in T 
cell number and activation within the pancreas correlated with the induction of an 






 cells. An exhaustive study of 
additional innate cells in both models remains to be done, but remains an important 
question, as the alteration of these cells likely has effects on the microenvironment 
cytokine milieu and thus, may polarize additional cell types from a pro- to anti-cancer 
phenotype.  
It is clear from the work described within this thesis, as well as in published work 
from many other groups, that mechanisms of immune tolerance begin early and thus, we 
will need to intervene with immunotherapy as early as possible. One future strategy must 
be to identify people who are at risk for developing cancer and this will become easier 
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with improved diagnostics and recent efforts to sequence an individual’s cancer genome.  
However, even when it is possible to identify cancer at its earliest stages, more than one 
form of immunotherapy and/or traditional therapy will be necessary for successful cancer 
treatment. Combination therapy for cancer has been a long established principle; 
combinations of chemotherapy drugs or chemotherapy with radiation have been shown to 
be more efficacious in preventing recurrence than one modality alone.  The same 
principle holds true for immunotherapy; additional therapies directed at overcoming 
suppressive signals or re-directing suppressive into protective immune cell populations 
will be necessary in addition to cancer vaccines, if we intend to fulfill the promise of 
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